GSK plc 6-K, filed Oct 28, 2026
GSK plc (GSK)
6-K
2026-10-28
For: 2026-10-28
View Original
Added on
October 28, 2026
About this 6-K
GSK plc filed this 6-K on October 28, 2026.
GSK reported Q3 sales of £8.9 billion, up 5% at CER, with core operating profit up 5%. It reaffirmed 2026 guidance for turnover growth of 3% to 5% and core operating profit growth of 7% to 9%. AI summary
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK delivers strong Q3 performance and continued
momentum
|
|
|
|
Strong Specialty Medicines performance drives sales and core
operating profit growth
|
|
|
|
|
|
●
|
Total
Q3 sales £8.9 billion +4% AER; +5% CER
|
|
●
|
Specialty
Medicines sales £3.9 billion (+15%); HIV sales £2.1
billion (+10%), Respiratory, Immunology & Inflammation
£1.1 billion (+21%); Oncology £0.6 billion
(+23%)
|
|
●
|
Vaccines
sales £2.6 billion (-2%); Shingrix £0.8 billion (-5%);
Meningitis vaccines £0.6 billion (+12%); and Arexvy £0.2 billion
(-24%)
|
|
●
|
General
Medicines sales £2.4 billion (stable); Trelegy £0.8 billion
(+8%)
|
|
●
|
Total
operating profit -16% and Total EPS -21% driven by Major
restructuring charges of £328 million related to the
Accelerate Growth programme and lower other net operating income,
partly offset by Core operating profit growth
|
|
●
|
Core
operating profit +5% and Core EPS +1% reflecting higher sales,
favourable product and regional mix and higher royalty income,
partly offset by increased investment in R&D and new asset
launches and higher finance costs
|
|
●
|
Cash
generated from operations of £3.1 billion with free cash flow
of £2.1 billion
|
|
(Financial
Performance – Q3 2026 results unless otherwise stated, growth
% and commentary at CER as defined on page 43. The quarter and year
to date adverse currency impact on AER versus CER primarily
reflected the strengthening of Sterling against the USD. See page 8
for further details.)
|
|
|
|
|
|
|
|
|
|
|
||
|
|
Q3 2026
|
Year to date
|
|
||||||
|
|
£m
|
%
AER
|
%
CER
|
£m
|
%
AER
|
%
CER
|
|
||
|
Turnover
|
8,887
|
4
|
5
|
24,925
|
4
|
5
|
|
||
|
Total
operating profit
|
2,127
|
(18)
|
(16)
|
4,901
|
(28)
|
(25)
|
|
||
|
Total
operating margin %
|
23.9%
|
(6.4ppts)
|
(6.1ppts)
|
19.7%
|
(8.7ppts)
|
(8.2ppts)
|
|
||
|
Total
EPS
|
38.5p
|
(23)
|
(21)
|
92.5p
|
(26)
|
(23)
|
|
||
|
Core
operating profit
|
3,076
|
3
|
5
|
8,526
|
5
|
7
|
|
||
|
Core
operating margin %
|
34.6%
|
(0.3ppts)
|
(0.1ppts)
|
34.2%
|
0.3ppts
|
0.7ppts
|
|
||
|
Core
EPS
|
54.6p
|
(1)
|
1
|
151.6p
|
4
|
6
|
|
||
|
Cash
generated from operations
|
3,122
|
24
|
|
7,378
|
18
|
|
|
||
|
|
|
|
|||||||
|
Continued pipeline progress:
|
|
||||||||
|
●
|
Hibsago approved in US and Japan, with data showing
unprecedented functional cure rates and potential to redefine
treatment of chronic hepatitis B
|
|
|||||||
|
●
|
Jemperli approved in US as first immunotherapy for adults
with dMMR/MSI-H locally advanced rectal cancer
|
|
|||||||
|
●
|
Positive
registrational data for Jideytro in first-line ROS1-positive
non-small cell lung cancer (approved in US in second-line in
July)
|
|
|||||||
|
●
|
Promising
first global data for Ris-Rez in lung cancer; and positive phase I
data for Mo-Rez in ovarian cancer
|
|
|||||||
|
●
|
Shingrix pre-filled syringe approved in Japan, simplifying
administration
|
|
|||||||
|
●
|
mRNA
seasonal influenza (flu) vaccine phase III trial initiated,
following positive phase II data
|
|
|||||||
|
●
|
On
track to start 22 phase III trials in 2026 with 18 starts to
date
|
|
|||||||
|
|
|
||||||||
|
Growth outlooks:
|
|||||||||
|
●
2026 guidance
reaffirmed with expected growth in: turnover 3% to 5%; Core OP 7%
to 9%; Core EPS 7% to 9%
|
|||||||||
|
● On
track for 2031 sales outlook of more than £40
billion
|
|||||||||
|
●
Operating
margin stable to improving through dolutegravir loss of exclusivity
period of 2028-2030
|
|||||||||
|
|
|
|
|
Shareholder returns:
|
||
|
●
|
Q3 2026
dividend of 17p declared; 70p expected for full year
2026
|
|
|
|
|
|
|
Luke Miels, Chief Executive Officer, GSK:
“GSK
has delivered another strong quarter, with our key growth drivers
and new launches performing well. We remain focused on operational
delivery, execution and accelerating R&D. Over recent months we
have received 3 new specialty medicine approvals in the US:
Hibsago, which has the
potential to transform the treatment of chronic hepatitis B;
Jideytro in non-small cell
lung cancer; and Jemperli
in rectal cancer. More broadly, in the late-stage portfolio, we are
on track to start 22 phase III trials this
year.”
|
|
|
Guidance all at CER. The Total results are presented in summary
above and on page 7 and Core results reconciliations are presented
on pages 16 and 18. Core results are a non-IFRS measure that may be
considered in addition to, but not as a substitute for, or superior
to, information presented in accordance with IFRS. The following
terms are defined on pages 43-44: Core results, AER% growth, CER%
growth and other non-IFRS measures. GSK provides guidance on a Core
results basis only for the reasons set out on page 14. All
expectations, guidance and outlooks regarding future performance
and dividend payments should be read together with ‘Guidance
and outlooks, assumptions and cautionary statements’ on pages
45-46. Abbreviations are defined on page 49.
2026 Guidance
GSK
reaffirms its full-year 2026 guidance at constant exchange rates
(CER).
|
|
|
Turnover is expected to
increase between 3% to 5%, at the upper half of the
range
|
|
Core operating profit is
expected to increase between 7% to 9%, at the upper half of the
range
|
|
Core earnings per share is expected to increase between 7% to 9%, at the
lower half of the range
|
This
guidance is supported by the following turnover expectations for
full-year 2026 at CER.
|
|
|
|
|
Specialty Medicines
|
–
|
expected
increase at a low double-digit percentage
|
|
Vaccines
|
–
|
expected
to be broadly stable to an increase at a low single-digit
percentage
|
|
General Medicines
|
–
|
expected
decline of a mid-single digit to low single-digit
percentage
|
Core
operating profit is expected to grow at the upper half of the 7 to
9 per cent range at CER. GSK continues to expect to deliver gross
margin accretion due to improved product mix from Specialty
Medicines growth and continued operational efficiencies. In
addition, GSK anticipates further leverage in Operating profit as
we accelerate ongoing productivity initiatives and take a
returns-based approach to SG&A investments, with SG&A
expected to be broadly stable year-on-year. R&D is expected to
grow significantly ahead of sales as we accelerate investments in
the pipeline as part of the Accelerate Growth programme while
driving operational efficiencies. Royalty income is expected to be
around £900 million.
Core
earnings per share is expected to increase at the lower half of the
7 to 9 per cent range at CER, reflecting higher interest charges of
around £700-750 million, including the impact of the Nuvalent
acquisition, and the tax rate which is expected to rise to around
17.5%, offset by the expected benefit from the share buyback
programme. Expectations for non-controlling interests remain
unchanged relative to 2025.
Agreement with US Government
to lower the cost of prescription medicines for American
patients
As
previously announced, on 19 December 2025, GSK entered into an
agreement with the US Administration to lower the cost of
prescription medicines for American patients and exclude both GSK
and ViiV Healthcare from Section 232 tariffs for three years. On 9
April 2026, GSK, ViiV Healthcare, and the US Government entered
into a definitive agreement reflecting Section 232 tariff relief
through 20 January 2029 (subject to implementation and ongoing
compliance). As part of that implementation, GSK and ViiV
Healthcare each signed a GENEROUS Model Manufacturer Participation
Agreement with the Centers for Medicare and Medicaid Services
effective 15 June 2026. With these agreements GSK and ViiV
Healthcare have committed certain products to participate in the
voluntary GENEROUS Model. GSK and ViiV have also entered into
GENEROUS Model Supplemental Rebate Agreements with several
interested states and will work with the other states going forward
to execute Supplemental Rebate Agreements as requested. Our full
year guidance is inclusive of the expected impact of these
agreements.
Dividend policy
The
Dividend policy and the expected pay-out ratio remain unchanged.
Consistent with this, GSK has declared a dividend for Q3 2026 of
17p per share. GSK's future dividend policy and guidance regarding
the expected dividend pay-out in 2026 are provided on page
30.
GSK
completed the £2 billion share buyback programme announced in
FY 2024 in Q2 2026.
Exchange rates
If
exchange rates were to hold at the closing rates on 30 September
2026 ($1.33/£1, €1.17/£1 and Yen 209/£1) for
the rest of 2026, the estimated impact on 2026 Sterling turnover
growth for GSK would be -1% and if exchange gains or losses were
recognised at the same level as in 2025, the estimated impact on
2026 Sterling Core Operating Profit growth for GSK would be
-3%.
Results presentation
A
conference call and webcast for investors and analysts of the
quarterly results will be hosted by Luke Miels, CEO, at 12:00 GMT
(08:00 EDT) on 28 October 2026. Presentation materials will be
published on www.gsk.com
prior to the webcast and a transcript of the webcast will be
published subsequently.
Notwithstanding
the inclusion of weblinks, information available on the
company’s website, or from non GSK sources, is not
incorporated by reference into this Results
Announcement.
Performance: Turnover
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Turnover
|
Q3 2026
|
Year to date
|
|||||||||||||||||||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|||||||||||||||||||||
|
HIV
|
2,116
|
9
|
10
|
6,018
|
9
|
10
|
|||||||||||||||||||||
|
Respiratory,
Immunology & Inflammation (RI&I)
|
1,139
|
19
|
21
|
3,164
|
16
|
18
|
|||||||||||||||||||||
|
Oncology
|
622
|
22
|
23
|
1,703
|
21
|
22
|
|||||||||||||||||||||
|
Specialty Medicines
|
3,877
|
14
|
15
|
10,885
|
13
|
14
|
|||||||||||||||||||||
|
Shingles
(Shingrix)
|
780
|
(6)
|
(5)
|
2,694
|
6
|
6
|
|||||||||||||||||||||
|
Meningitis
|
599
|
11
|
12
|
1,396
|
10
|
11
|
|||||||||||||||||||||
|
RSV
(Arexvy)
|
195
|
(22)
|
(24)
|
452
|
14
|
12
|
|||||||||||||||||||||
|
Influenza
|
177
|
(18)
|
(17)
|
198
|
(11)
|
(9)
|
|||||||||||||||||||||
|
Other
Paediatric & Adult Vaccines
|
832
|
(1)
|
–
|
2,276
|
(6)
|
(5)
|
|||||||||||||||||||||
|
Vaccines
|
2,583
|
(4)
|
(2)
|
7,016
|
2
|
3
|
|||||||||||||||||||||
|
Respiratory
|
1,708
|
–
|
1
|
4,981
|
(6)
|
(4)
|
|||||||||||||||||||||
|
Other
General Medicines
|
719
|
(5)
|
(3)
|
2,043
|
(9)
|
(6)
|
|||||||||||||||||||||
|
General Medicines
|
2,427
|
(1)
|
–
|
7,024
|
(7)
|
(5)
|
|||||||||||||||||||||
|
Total
|
8,887
|
4
|
5
|
24,925
|
4
|
5
|
|||||||||||||||||||||
|
By Region:
|
|
|
|
|
|
|
|||||||||||||||||||||
|
US
|
4,931
|
8
|
10
|
12,976
|
5
|
7
|
|||||||||||||||||||||
|
Europe
|
1,928
|
3
|
3
|
6,053
|
11
|
8
|
|||||||||||||||||||||
|
International
|
2,028
|
(4)
|
(3)
|
5,896
|
(4)
|
(2)
|
|||||||||||||||||||||
|
Total
|
8,887
|
4
|
5
|
24,925
|
4
|
5
|
|||||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Financial
Performance – Q3 2026 results unless otherwise stated, growth
% and commentary at CER. The quarter and YTD adverse currency
impact on AER versus CER primarily reflected the strengthening of
Sterling against the USD. See page 8 for further
details.
|
|||||||||||||||||||||||||||
|
For
product list - see page 50
|
|||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
|
|
Q3 2026
|
Year to date
|
Key Drivers
|
||||||||||||||||||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
||||||||||||||||||||
|
Specialty
Medicines Total
|
3,877
|
14
|
15
|
10,885
|
13
|
14
|
Continued growth across disease areas, with strong performances in
HIV, Respiratory, Immunology & Inflammation, and
Oncology.
|
||||||||||||||||||||
|
HIV
|
2,116
|
9
|
10
|
6,018
|
9
|
10
|
In Q3
LAIs delivered 80% of total HIV growth. Strong underlying patient
demand of +7ppts for Cabenuva, Apretude and Dovato more than offset mature
portfolio decline, with additional favourable pricing from US
channel mix in Q3. US HIV sales increased 14% with LAIs
representing 35% of US HIV turnover.
|
||||||||||||||||||||
|
Dovato
|
754
|
8
|
9
|
2,169
|
13
|
14
|
Strong
demand across US and EU partly offset by the International region
where the DTG LoE has started to impact tender
volumes.
|
||||||||||||||||||||
|
Cabenuva
|
478
|
34
|
35
|
1,299
|
31
|
33
|
Contributed
>65% of total HIV growth in Q3, with strong demand across all
regions.
|
||||||||||||||||||||
|
Apretude
|
143
|
19
|
21
|
403
|
30
|
33
|
Growth
driven by continued strong demand in a competitive US long-acting
prevention market.
|
||||||||||||||||||||
|
RI&I
|
1,139
|
19
|
21
|
3,164
|
16
|
18
|
Growth
driven by Nucala and
Exdensur in respiratory and
Benlysta in
immunology.
|
||||||||||||||||||||
|
Nucala
|
582
|
17
|
18
|
1,676
|
16
|
18
|
Sustained
double-digit growth largely driven by US and International regions,
with increased demand across all indications enhanced by COPD
launches. Strong US volume growth was partially offset by continued
pricing pressures.
|
||||||||||||||||||||
|
Exdensur
|
27
|
–
|
–
|
56
|
–
|
–
|
Increasing
new patient starts in key growth markets US, Japan and Germany, and
geographic expansion with launches across other European and
International markets. Exdensur is now launched in 8 countries
globally.
|
||||||||||||||||||||
|
Benlysta
|
520
|
16
|
17
|
1,402
|
12
|
14
|
Strong
volume growth in Q3 and YTD, with bio-penetration rates having
increased across many markets.
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
|
|
Q3 2026
|
Year to date
|
Key Drivers
|
||||||||||||||||||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
||||||||||||||||||||
|
Oncology
|
622
|
22
|
23
|
1,703
|
21
|
22
|
Increasing
patient demand for Jemperli, Ojjaara/Omjjara and Blenrep, partially offset by a decrease
in Zejula. Jideytro, for the treatment of
TKI-pretreated ROS-1 positive NSCLC, was approved and launched in
the US in Q3 2026 with sales of £3 million.
|
||||||||||||||||||||
|
Jemperli
|
273
|
19
|
19
|
753
|
25
|
27
|
Continued
strong growth in Q3 and YTD across all regions. US continued to
grow double-digit, which reduced in Q3 as new patient starts
moderated. Strong growth continued in Europe and International
driven by launches and reimbursement expansion across
markets.
|
||||||||||||||||||||
|
Ojjaara/Omjjara
|
195
|
34
|
35
|
526
|
33
|
35
|
Higher
patient uptake across the regions and from continued commercial
launches across Europe and International markets. US volume growth
in Q3 and YTD was partly offset by continuing pricing
pressures.
|
||||||||||||||||||||
|
Zejula
|
104
|
(24)
|
(23)
|
319
|
(24)
|
(23)
|
US
continues to decline with volume impacted by the 2025 FDA label
update and new 2026 prior authorisation insurance requirements, and
adverse pricing impacts. Europe declined due to increased
competition.
|
||||||||||||||||||||
|
Blenrep
|
50
|
–
|
–
|
109
|
>100
|
>100
|
US
sales driven by patient uptake in both community and academic
settings. Continued geographic expansion with launches across
Europe and International markets. Blenrep is now launched in 28 countries
globally.
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
|
|
Q3 2026
|
Year to date
|
Key Drivers
|
||||||||||||||||||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
||||||||||||||||||||
|
Vaccines Total
|
2,583
|
(4)
|
(2)
|
7,016
|
2
|
3
|
Q3 decreases in Arexvy, Shingrix and Influenza partly offset by
Meningitis vaccines. YTD growth due to Shingrix and Meningitis vaccines partly
offset by Other Paediatric & Adult
Vaccines.
|
||||||||||||||||||||
|
Shingrix
|
780
|
(6)
|
(5)
|
2,694
|
6
|
6
|
Q3
decline driven by lower sales in International, primarily China,
partly offset by US pricing and inventory build in the quarter. YTD
growth was also driven by higher demand in Europe.
The
cumulative immunisation rate in the US reached 46%, up 3ppts
compared to 12 months earlier(1).
|
||||||||||||||||||||
|
Meningitis
|
599
|
11
|
12
|
1,396
|
10
|
11
|
Highest
ever sales quarter with growth delivered by Penmenvy continued post launch uptake
and Bexsero CDC stockpile
build and ordering patterns in the US. YTD growth included
outbreak-related demand for Bexsero in International and
Europe.
|
||||||||||||||||||||
|
Arexvy
|
195
|
(22)
|
(24)
|
452
|
14
|
12
|
Q3
decline due to lower market demand, as well as returns provision
adjustments in the US in Q3 2025, partly offset by growth in Europe
from uptake in Germany. YTD growth benefitted from Australian
tender deliveries.
|
||||||||||||||||||||
|
Influenza
|
177
|
(18)
|
(17)
|
198
|
(11)
|
(9)
|
Declining
due to US competitive pressure and delayed timing of
deliveries.
|
||||||||||||||||||||
|
Other
Paediatric & Adult Vaccines
|
832
|
(1)
|
–
|
2,276
|
(6)
|
(5)
|
Broadly
flat as MMR/V vaccine sales decreased due to the one-off sale of
bulk antigen in 2025 and lower demand in International, offset by
favourable CDC stockpile and channel inventory movements for
Boostrix in the US. YTD
decline was impacted by competitive pressure for Other Vaccines,
particularly Synflorix in
International.
|
||||||||||||||||||||
(1)
Based on data from IQVIA up until the end of Q2 2026
|
|
|
|
|
|
|
|
|
|
|
Q3 2026
|
Year to date
|
Key Drivers
|
||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
|
General Medicines Total
|
2,427
|
(1)
|
–
|
7,024
|
(7)
|
(5)
|
Broadly stable in the quarter with growth in Trelegy offset by declines in the other
Respiratory and Other General Medicines products. Decline YTD
with Trelegy
broadly stable and
declines across the broader portfolio.
|
|
Respiratory
|
1,708
|
–
|
1
|
4,981
|
(6)
|
(4)
|
Trelegy increased in Q3 driven by volume and pricing
adjustments, broadly stable YTD. Decreases in other respiratory
products due to continued competitive pressures and generic
erosion.
|
|
Trelegy
|
787
|
7
|
8
|
2,208
|
(2)
|
–
|
Sales
grew in Q3 across all regions. US sales in the quarter grew high
single-digit driven by increased volume and positive pricing
adjustments. YTD sales were broadly stable as growth in Europe and
International was offset by decreases in the US, where volumes
remain adversely impacted by Medicare benefit design changes and
continued pricing pressures.
|
|
Other
General Medicines
|
719
|
(5)
|
(3)
|
2,043
|
(9)
|
(6)
|
Decrease
in growth driven by continued competitive pressures and generic
competition across the portfolio and a reduction in contract
manufacturing sales.
|
By Region
|
|
|
|
|
|
|
|
|
|
|
Q3 2026
|
Year to date
|
Key Drivers
|
||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
|
US
|
4,931
|
8
|
10
|
12,976
|
5
|
7
|
Specialty
Medicines: Q3 +17%, YTD +16%
Growth
driven largely by patient demand in HIV, Oncology, Benlysta and Nucala.
Vaccines:
Q3 +2%, YTD +2%
Growth
primarily driven by favourable pricing and channel inventory
movements for Shingrix, CDC
stockpile and channel inventory movements for Boostrix and Penmenvy continued post launch uptake
partly offset by lower demand for Arexvy.
General
Medicines: Q3 +3%, YTD -7%
Trelegy growth in the quarter from sales volume and positive
pricing adjustments. YTD, Trelegy declines as volumes have been
impacted by Medicare benefit design changes and continued pricing
pressures. Decreases continued across the other respiratory and
Other General Medicine portfolios partially offset in the quarter
with price adjustments to Ventolin and Advair.
|
|
Europe
|
1,928
|
3
|
3
|
6,053
|
11
|
8
|
Specialty
Medicines: Q3 +9%, YTD +9%
Growth
driven by Oncology, Nucala,
Benlysta and
HIV.
Vaccines:
Q3 +2%, YTD +15%
Q3
growth driven by Arexvy
uptake in Germany, with significant increased demand for
Shingrix across Europe
YTD.
General
Medicines: Q3 -3%, YTD -2%
Low
single-digit decline, with growth in Trelegy and Anoro more than offset by decreases in
other respiratory products.
|
|
International
|
2,028
|
(4)
|
(3)
|
5,896
|
(4)
|
(2)
|
Specialty
Medicines: Q3 +13%, YTD +13%
Growth
driven by Oncology, Nucala
and Benlysta.
Vaccines:
Q3 -15%, YTD -9%
Q3
decline primarily due to lower sales of Shingrix, primarily in China and the
one-off sale of MMR/V bulk antigen in 2025. YTD sales reflect
competitive pressure for Other Vaccines, partly offset by growth in
Arexvy from Australian
tender deliveries.
General
Medicines: Q3 -2%, YTD -4%
Growth
in Trelegy and Anoro more than offset by decreases
across other respiratory and Other General Medicine products, which
included reductions in contract manufacturing income.
|
Financial Performance - Core results
Core
operating profit growth in Q3 2026 and YTD primarily reflected
higher turnover, favourable product and regional mix, ongoing
productivity initiatives and supply chain optimisation, higher
royalty income, and favourable net legal settlements and expenses
in Q1 2026, partly offset by increased investment in R&D and
new asset launches.
The
increase in Core EPS in Q3 2026 and YTD primarily reflected the
growth in Core operating profit and the share buyback, partly
offset by higher net finance expenses primarily due to Nuvalent, a
higher effective tax rate and higher NCIs.
|
|
|
|
|
|
|
|
|
Core Results
|
Q3 2026
|
Year to date
|
||||
|
|
£m
|
%
AER
|
%
CER
|
£m
|
%
AER
|
%
CER
|
|
Turnover
|
8,887
|
4
|
5
|
24,925
|
4
|
5
|
|
Cost of
sales
|
(2,040)
|
(1)
|
–
|
(5,639)
|
(2)
|
(2)
|
|
% of sales
|
23.0%
|
(1.1)
|
(1.2)
|
22.6%
|
(1.4)
|
(1.6)
|
|
Selling,
general and administration
|
(2,155)
|
–
|
1
|
(6,329)
|
–
|
1
|
|
% of sales
|
24.2%
|
(1.0)
|
(1.1)
|
25.4%
|
(0.9)
|
(1.0)
|
|
Research
and development
|
(1,874)
|
21
|
22
|
(5,088)
|
14
|
16
|
|
% of sales
|
21.1%
|
2.9
|
2.9
|
20.4%
|
1.9
|
1.9
|
|
Royalty
income
|
258
|
24
|
24
|
657
|
4
|
3
|
|
Core operating profit
|
3,076
|
3
|
5
|
8,526
|
5
|
7
|
|
% of sales
|
34.6%
|
(0.3)
|
(0.1)
|
34.2%
|
0.3
|
0.7
|
|
Core
net finance expense
|
(197)
|
49
|
50
|
(461)
|
29
|
30
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(2)
|
|
|
(9)
|
|
|
|
Core profit before taxation
|
2,877
|
1
|
3
|
8,056
|
3
|
6
|
|
Taxation
|
(490)
|
8
|
9
|
(1,405)
|
6
|
8
|
|
Tax rate %
|
17.0%
|
|
|
17.4%
|
|
|
|
Core profit after taxation
|
2,387
|
–
|
1
|
6,651
|
3
|
6
|
|
Core
profit attributable to non-controlling interests
|
198
|
12
|
14
|
562
|
10
|
12
|
|
Core
profit attributable to shareholders
|
2,189
|
|
|
6,089
|
|
|
|
|
2,387
|
–
|
1
|
6,651
|
3
|
6
|
|
Core
Earnings per share
|
54.6p
|
(1)
|
1
|
151.6p
|
4
|
6
|
|
Financial
Performance – Q3 2026 results unless otherwise stated, growth
% and commentary at CER. See page 7 for Total results financial
performance commentary. In the quarter and YTD, the adverse
currency impact on AER versus CER primarily reflected the
strengthening of Sterling against the USD. See page 8 for further
details. Reconciliations between Total results and Core results Q3
2026, Q3 2025, 9 months 2026 and 9 months 2025 are set out on pages
16 and 18.
|
||||||
Core
cost of sales as a percentage of sales decreased in Q3 2026 and YTD
primarily due to favourable product and regional mix driven by
higher specialty sales and the growth of higher margin Vaccines
products YTD, as well as a favourable YTD comparator due to supply
chain optimisation charges incurred in Q2 2025.
Core
SG&A was broadly stable in Q3 2026 and YTD with disciplined
investment to support launches for new assets including
Blenrep and Exdensur partly offset by ongoing
productivity initiatives. The YTD also has net favourability on
legal settlements and expenses equivalent to around 1ppt
impact.
Core
R&D investment increased in Q3 2026 and YTD reflecting
progression across the portfolio, primarily in Oncology. This
included acceleration in work on ADCs Ris-Rez and Mo-Rez, progress
on velzatinib for GIST and, following the Nuvalent acquisition, on
Jideytro (zidesamtinib),
approved by the FDA in the quarter, and neladalkib. In Specialty
Medicines, increased investment was driven by efimosfermin acquired
in Q3 2025, depemokimab COPD indication and all indications of
felcorekibart (the anti-TSLP monoclonal antibody). Growth was
partly offset by lower spend on bepirovirsen which was filed in Q1
2026. Investment also increased on clinical trial programmes
associated with mRNA seasonal flu vaccines.
Core
royalty income increased in Q3 2026 and YTD primarily due to higher
Kesimpta(1) royalties, partly
offset in the YTD by historic royalties recognised in Q2 2025
related to the settlement of an IP dispute.
The
increase in net finance costs in Q3 2026 and YTD was driven by
higher interest expense primarily related to the Nuvalent
acquisition, partly offset by a net favourable variance on hedging
activities.
The
effective tax rate on Core profits was broadly in line with
expectations for the year.
Core
NCIs in the quarter and YTD were higher primarily due to higher
core profit allocations from ViiV Healthcare.
(1) Kesimpta is manufactured by and a trademark of Novartis
AG
Financial performance - Total results
Total
operating profit decreased in Q3 2026 primarily due to Major
Restructuring charges of £328 million related to the
Accelerate Growth programme and lower other net operating income,
partly offset by higher Core operating profit. YTD profit
also decreased primarily due to higher impairments and higher CCL
charges, partly offset by higher other net operating income and
Core operating profit.
Total
EPS decreased in Q3 2026 and YTD primarily due to lower Total
operating profit, higher finance expenses, and higher NCIs in Q3,
partly offset by the share buyback and a lower effective tax
rate.
|
|
|
|
|
|
|
|
|
Total Results
|
Q3 2026
|
Year to date
|
||||
|
|
£m
|
%
AER
|
%
CER
|
£m
|
%
AER
|
%
CER
|
|
Turnover
|
8,887
|
4
|
5
|
24,925
|
4
|
5
|
|
Cost of
sales
|
(2,390)
|
6
|
7
|
(6,531)
|
3
|
3
|
|
% of sales
|
26.9%
|
0.5
|
0.4
|
26.2%
|
(0.2)
|
(0.5)
|
|
Selling,
general and administration
|
(2,383)
|
6
|
7
|
(6,704)
|
4
|
5
|
|
% of sales
|
26.8%
|
0.6
|
0.5
|
26.9%
|
0.1
|
–
|
|
Research
and development
|
(1,983)
|
17
|
18
|
(7,141)
|
38
|
39
|
|
% of sales
|
22.3%
|
2.6
|
2.5
|
28.6%
|
7.1
|
7.0
|
|
Royalty
income
|
258
|
24
|
24
|
657
|
4
|
3
|
|
Other
operating income/(expense)
|
(262)
|
>100
|
>100
|
(305)
|
>100
|
>100
|
|
Operating profit
|
2,127
|
(18)
|
(16)
|
4,901
|
(28)
|
(25)
|
|
% of sales
|
23.9%
|
(6.4)
|
(6.1)
|
19.7%
|
(8.7)
|
(8.2)
|
|
Net
finance expense
|
(190)
|
35
|
36
|
(459)
|
20
|
21
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(2)
|
|
|
(9)
|
|
|
|
Profit before taxation
|
1,935
|
(21)
|
(19)
|
4,433
|
(31)
|
(28)
|
|
Taxation
|
(232)
|
(26)
|
(24)
|
(338)
|
(62)
|
(58)
|
|
Tax rate %
|
12.0%
|
|
|
7.6%
|
|
|
|
Profit after taxation
|
1,703
|
(21)
|
(19)
|
4,095
|
(26)
|
(23)
|
|
Profit
attributable to non-controlling interests
|
160
|
22
|
25
|
380
|
(21)
|
(18)
|
|
Profit
attributable to shareholders
|
1,543
|
|
|
3,715
|
|
|
|
|
1,703
|
(21)
|
(19)
|
4,095
|
(26)
|
(23)
|
|
Earnings
per share
|
38.5p
|
(23)
|
(21)
|
92.5p
|
(26)
|
(23)
|
|
Financial
Performance – Q3 2026 results unless otherwise stated, growth
% and commentary at CER. See page 6 for Core results financial
performance commentary.
In the
quarter and YTD, the adverse currency impact on AER versus CER
primarily reflected the strengthening of Sterling against the USD.
See page 8 for further details. Reconciliations between Total
results and Core results Q3 2026, Q3 2025, 9 months 2026 and 9
months 2025 are set out on pages 16 and 18.
|
||||||
Total cost of sales
increased in Q3 2026 and YTD due to Major restructuring charges
related to the Accelerate Growth programme taken in Q3 and higher
impairments in Q2, partly offset by Core cost of sales
benefits.
Total SG&A
increased in the quarter and YTD primarily due to Major
restructuring charges related to the Accelerate Growth programme
taken in Q3, as well as Nuvalent transaction costs. YTD also
included amounts reclassified from the foreign currency translation
reserve to the income statement upon the liquidation of a
subsidiary, and acquisition and integration costs related to RAPT
Therapeutics ("RAPT"). Core SG&A was broadly stable in Q3 2026
and YTD.
Total R&D
growth in Q3 2026 was driven by Core R&D investment. YTD growth
included the impact of higher impairments in Q2 2026 related to
camlipixant (£1,334 million) and the termination of assets
related to the collaboration with Alector (£371 million). See
page 19 for more details.
Total royalty
income increased in the quarter and YTD driven by Core
royalties.
Other operating
income/(expense) in Q3 2026 included a charge of £289 million
(Q3 2025: £280 million) arising from the remeasurement of
CCLs, partly offset by net income of £27 million (Q3 2025:
£304 million). The YTD included a charge of £1,040
million (YTD 2025: £193 million) principally arising from the
remeasurement of CCLs, partly offset by net income of £735
million (YTD 2025: £326 million) primarily related to profit
on the sale of the Rockville manufacturing facility and the
divestment of linerixibat. See pages 17 and 19 for further
details.
Net finance costs
increased in Q3 2026 and YTD mainly due to Core net finance
expenses.
The effective tax
rate on Total results reflected the different tax effects of the
various Adjusting items included in Total results. Issues related
to taxation are described in Note 14, ‘Taxation’ in the
Annual Report 2025. The Group continues to believe it has made
adequate provision for the liabilities likely to arise from periods
that are open and not yet agreed by relevant tax authorities. The
ultimate liability for such matters may vary from the amounts
provided and is dependent upon the outcome of agreements with
relevant tax authorities.
The increase in
Total NCIs in Q3 was driven by higher core profit allocations from
ViiV Healthcare. The YTD decrease primarily reflected higher
remeasurement charges on the Shionogi-ViiV CCL.
Exchange rates and impact on results
GSK
operates in many countries and earns revenues and incurs costs in
many currencies. The results of the Group, as reported in Sterling,
are affected by movements in exchange rates between Sterling and
other currencies. Average exchange rates, as modified by specific
transaction rates for large transactions, prevailing during the
period, are used to translate the results and cash flows of
overseas subsidiaries, associates and joint ventures into Sterling.
Period-end rates are used to translate the net assets of those
entities. The currencies which most influenced these translations
and the relevant exchange rates were:
|
|
|
|
|
|
|
|
|
|
|
Q3 2026
|
Q3
2025
|
YTD 2026
|
YTD
2025
|
2025
|
||
|
|
|
|
|
|
|
||
|
Average
rates:
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.34
|
1.33
|
1.34
|
1.31
|
1.31
|
|
|
|
Euro/£
|
1.17
|
1.16
|
1.16
|
1.18
|
1.17
|
|
|
|
Yen/£
|
213
|
198
|
213
|
195
|
198
|
|
|
|
|
|
|
|
||
|
Period-end
rates:
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.33
|
1.34
|
1.33
|
1.34
|
1.35
|
|
|
|
Euro/£
|
1.17
|
1.14
|
1.17
|
1.14
|
1.15
|
|
|
|
Yen/£
|
209
|
199
|
209
|
199
|
211
|
In Q3
2026 and YTD, the adverse currency impact primarily reflected the
strengthening of Sterling against the US Dollar, particularly in Q1
2026, as well as the Yen and emerging market currencies, partly
offset in the YTD by strengthening of the Euro. Exchange movements
on the settlement of intercompany transactions had a minimal impact
on Total and Core EPS in the quarter and YTD.
Cash generation
Cash flow
|
|
|
|
|
|
|
|
Q3 2026
£m
|
Q3
2025
£m
|
9 months 2026
£m
|
9
months 2025
£m
|
|
Cash
generated from operations (£m)
|
3,122
|
2,520
|
7,378
|
6,254
|
|
Total
net cash inflow/(outflow) from operating activities
(£m)
|
2,809
|
2,222
|
6,640
|
5,463
|
|
Free
cash inflow/(outflow)* (£m)
|
2,078
|
1,246
|
4,887
|
3,069
|
|
Free
cash flow growth/(decline) (%)
|
67%
|
(6%)
|
59%
|
58%
|
|
Free
cash flow conversion* (%)
|
>100%
|
62%
|
>100%
|
60%
|
|
Total
net debt** (£m)
|
20,739
|
14,444
|
20,739
|
14,444
|
|
*
Free cash flow and free cash flow conversion are defined on page
43. Free cash flow is analysed on page 34.
|
||||
|
**
Total net debt is defined on page 44. Net debt is analysed on page
34.
|
||||
Q3 2026
Cash
generated from operations for the quarter was £3,122 million
(Q3 2025: £2,520 million). The increase primarily
reflected higher Core operating profit and favourable timing and
movements on trade receivables, payables and returns and rebates,
partly offset by an adverse exchange rate impact. The increase also
reflected a favourable comparator to £565 million Zantac settlement payments in Q3 2025,
partly offset by the £268 million cash settlement from CureVac
received in Q3 2025.
Total
contingent consideration cash payments in the quarter were
£435 million (Q3 2025: £326 million).
£346 million (Q3 2025: £321 million) of these
were recognised in cash flows from operating activities, including
cash payments made to Shionogi & Co. Ltd ("Shionogi") of
£342 million (Q3 2025:
£306 million).
Free
cash inflow was £2,078 million for the quarter (Q3 2025:
£1,246 million). The increase was primarily driven by
higher cash generated from operations and lower capital expenditure
on intangible assets.
9 months 2026
Cash
generated from operations was £7,378 million (9 months 2025:
£6,254 million). The increase reflected higher Core operating
profit, favourable timing and movements on trade receivables and
payables, partly offset by an adverse exchange rate impact, as well
as adverse timing and movements on returns and rebates. The
increase also reflected a favourable comparator to £688
million Zantac settlement
payments in YTD 2025, partly offset by the cash settlement from
CureVac (of which the majority was received in
2025).
Total
contingent consideration cash payments in 9 months 2026 were
£1,191 million (9 months 2025: £1,000 million).
£1,095 million (9 months 2025: £989 million) of
these were recognised in cash flows from operating activities,
including cash payments made to Shionogi of
£1,052 million (9 months 2025:
£956 million).
Free
cash inflow was £4,887 million for 9 months 2026 (9 months
2025: £3,069 million). The increase was driven by higher cash
generated from operations, lower capital expenditure on intangible
assets, higher proceeds from the sale of intangible assets,
including the divestment of linerixibat, and the special dividend
of $250 million (£187 million) related to the ViiV
shareholding restructure.
Total Net debt
At 30
September 2026, net debt was £20,739 million, compared with
£14,453 million at 31 December 2025, comprising gross debt of
£23,701 million and cash and liquid investments of £2,962
million. See net debt information on page 34.
Net
debt increased by £6,286 million primarily due to net
acquisition costs for Nuvalent £7,143 million, RAPT
£1,404 million and 35Pharma Inc. £700 million, dividends
paid to shareholders of £2,052 million, shares purchased as
part of the share buyback programme (completed in June 2026) of
£634 million and an exchange loss on net debt of £85
million. This was partly offset by primarily the free cash inflow
of £4,887 million and £386 million related to the
disposal of the Rockville site including proceeds and a reduction
in lease liabilities.
At 30
September 2026, GSK had short-term borrowings (including overdrafts
and lease liabilities) repayable within 12 months of £2,001
million and £2,978 million repayable in the subsequent
year.
|
|
|
|
|
|
|
Contents
|
Page
|
|
Q3 2026
pipeline highlights
|
11
|
|
Responsible
business
|
13
|
|
Total
and Core results
|
14
|
|
Income
statement
|
20
|
|
Statement
of comprehensive income
|
21
|
|
Balance
sheet
|
22
|
|
Statement
of changes in equity
|
23
|
|
Cash
flow statement
|
24
|
|
Sales
tables
|
25
|
|
Segment
information
|
28
|
|
Legal
matters
|
29
|
|
Returns
to shareholders
|
30
|
|
Additional
information
|
31
|
|
R&D
commentary
|
35
|
|
Reporting
definitions
|
43
|
|
Guidance
and outlooks, assumptions and cautionary statements
|
45
|
|
Independent
Auditor's review report to GSK plc
|
47
|
|
Glossary
of terms
|
49
|
|
|
|
|
|
|
Contacts
|
|||
|
GSK plc
(LSE/NYSE:GSK) is a global biopharma company with a purpose to
unite science, technology, and talent to get ahead of disease
together. Find out more at www.gsk.com.
|
|||
|
|
|
|
|
|
GSK enquiries:
|
|
|
|
|
Media
|
Tim
Foley
|
+44 (0)
7780 494750
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington)
|
|
|
|
|
|
|
Investor
Relations
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Joanna
Tuplin
|
+44 (0)
7788 351650
|
(London)
|
|
|
Sam
Piper
|
+44 (0)
7824 525779
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
7823 523885
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
|
|
|
|
|
|
Registered in England & Wales:
No.
3888792
|
|||
|
|
|||
|
Registered Office:
79 New
Oxford Street
London,
WC1A
1DG
|
|||
Q3 2026 pipeline highlights (since 28 July 2026)
|
|
|
|
|
|
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
Regulatory approvals or other regulatory actions
|
Jemperli
|
Stage
II and stage III microsatellite instability-high (MSI-H) / mismatch
repair deficient (dMMR) locally advanced rectal cancer
|
Regulatory
approval (US)
|
|
Hibsago
|
Chronic
Hepatitis B (CHB)
|
Regulatory
approval (JP, US)
|
|
|
Arexvy
|
Respiratory
Syncytial Virus (RSV)
Immunocompromised
(IC) adults aged 18 years and older
|
Regulatory
approval (US)
|
|
|
Shingrix
|
Shingles
(prefilled syringe presentation)
|
Regulatory
approval (JP)
|
|
|
Regulatory submissions or acceptances
|
Ventolin
|
Low
carbon MDI (asthma)
|
Regulatory
submission (EU)
|
|
Jemperli
|
AZUR-1
(rectal cancer)
|
Regulatory
submission (US)
|
|
|
Phase III data readouts or other significant events
|
Jideytro
|
ARROS-1
(treatment naive ROS 1+non-small cell lung cancer)
|
Positive
phase I/II (registrational) data readout
|
|
Cabenuva
|
CROWN
(HIV, unsuppressed)
|
Positive
phase IIIb topline data readout
|
|
|
Zejula
|
GLIOFOCUS
(glioblastoma)
|
Orphan
Drug Designation (EU)
|
|
|
Double-target
HA-NA seasonal flu
|
Seasonal
mRNA influenza virus vaccine candidate
|
Fast
Track Designation (US)
|
|
|
RSV/hMPV
investigational combination vaccine
|
Respiratory
Syncytial Virus/Human Metapneumovirus (RSV/hMPV)
|
Fast
Track Designation (US)
|
Anticipated pipeline milestones
|
|
|
|
|
||||
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
||||
|
H2 2026
|
Exdensur
|
OCEAN
(eosinophilic granulomatosis with polyangiitis)
|
Phase
III data readout
|
||||
|
neladalkib
|
Non-small
cell lung cancer (pre-treated ALK+)
|
Regulatory
decision (US)
|
|||||
|
Jideytro
|
Non-small
cell lung cancer (treatment naïve ROS 1+)
|
Regulatory
submission (US)
|
|||||
|
cabotegravir
|
3x a
year prevention (HIV)
|
Phase
IIb (pivotal) data readout
|
|||||
|
cabotegravir
|
3x a
year prevention (HIV)
|
Regulatory
submission (US)
|
|||||
|
H1 2027
|
Exdensur
|
OCEAN
(eosinophilic granulomatosis with polyangiitis)
|
Regulatory
submission (US, EU, CN, JP)
|
||||
|
Ventolin
|
Low
carbon MDI (asthma)
|
Regulatory
decision (EU)
|
|||||
|
Ventolin
|
Low
carbon MDI (asthma)
|
Regulatory
submission (US)
|
|||||
|
Jemperli
|
AZUR-1
(rectal cancer)
|
Regulatory
submission (JP)
|
|||||
|
cabotegravir
|
3x a
year prevention (HIV)
|
Regulatory
decision (US)
|
|||||
|
Arexvy
|
RSV,
adults aged 18-59
|
Phase
III data readout (CN)
|
|||||
|
Bexsero
|
Meningococcal
B (infants)
|
Regulatory
submission (US)
|
|||||
|
bepirovirsen
|
B-WELL
1/2 (chronic hepatitis B)
|
Regulatory
decision (EU, CN)
|
|||||
|
GSK'116
(varicella vaccine)
|
Varicella
new seed, individuals 12 months of age and older
|
Phase
III data readout
|
|||||
|
neladalkib
|
Non-small
cell lung cancer (pre-treated ALK+)
|
Regulatory
submission (EU)
|
|||||
|
Jideytro
|
Non-small
cell lung cancer (pre-treated ROS 1+)
|
Regulatory
submission (EU)
|
|||||
|
|
|||||||
|
|
|
|
|
Timing |
Medicine/vaccine
|
Trial
(indication, presentation)
|
Event
|
|
|
|
|
|
H2 2027 |
Exdensur
|
OCEAN
(eosinophilic granulomatosis with polyangiitis)
|
Regulatory decision
(US, JP)
|
|
|
|
|
Jemperli |
AZUR-1
(rectal cancer)
|
Regulatory
submission (EU, CN)
|
||
|
|
|
|
Jemperli
|
AZUR-1
(rectal cancer)
|
Regulatory decision
(EU)
|
||
|
|
|
|
Ris-Rez
|
EMBOLD
SCLC-301 (small cell lung cancer)
|
Phase
III data readout
|
||
|
|
|
|
velzatinib
|
GIST - 1L or 2L therapy for advanced gastrointestinal stromal tumors |
Phase
III data readout
|
||
|
|
|
|
Jideytro
|
Non-small cell lung
cancer (treatment naïve ROS1+)
|
Regulatory decision
(US)
|
||
|
|
|
|
cabotegravir +
rilpivirine
|
CUATRO,
3x a year treatment (HIV)
|
Phase
III data readout
|
||
|
|
|
|
cabotegravir +
rilpivirine
|
CUATRO,
3x a year treatment (HIV)
|
Regulatory
submission (US)
|
||
|
|
|
|
Arexvy
|
RSV,
adults aged 18-59
|
Regulatory
submission (CN)
|
||
|
|
|
|
Arexvy
|
RSV,
adults aged 60+
|
Regulatory decision
(CN)
|
||
|
|
|
|
Bexsero
|
Meningococcal B
(infants)
|
Regulatory decision (US) | ||
|
|
|
|
|
GSK'116
(varicella vaccine)
|
Varicella new seed,
individuals 12 months of age and older
|
Regulatory
submission (US)
|
|
Refer
to pages 35 to 42 for further details on several key medicines and
vaccines in development by therapy area.
Progress on areas for responsible business
Being a
responsible business is a fundamental part of GSK’s strategy
and supports long-term performance. Annual progress against
GSK’s responsible business priorities is detailed in the
Annual(1)
and Responsible
Business(2) Reports with
incremental updates shared each quarter. Highlights below include
activity since Q2 2026 results.
Access
|
|
|
|
●
|
In
October, ViiV Healthcare announced(3) an agreement with
Axmed to expand access to HIV medicines in more than 50
middle-income countries. With most new HIV cases reported in low-
and middle-income countries, expanding choice in HIV care options
remains a key priority. This agreement aims to offer a simpler
route for local governments and healthcare institutions to access
more choice in HIV care to support countries’ HIV
response.
|
Global health and health security
|
|
|
|
●
|
Dengue
remains a major unmet global health challenge with hundreds of
millions of infections estimated each year and limited treatment
options. In August, Chugai and GSK signed(4) an exclusive
license agreement to develop a preclinical anti-dengue virus
antibody which, if successful, could help manage dengue fever and
other flavivirus infections.
|
|
●
|
With
the growing threat of drug-resistance in malaria treatment, there
is an urgent need for continued innovation. Through GSK’s
partnership with Medicines for Malaria Venture, a potential new
phase II malaria drug, GSK701, has shown(5) to be a promising
candidate for uncomplicated malaria that could help meet a need for
new medicines.
|
|
●
|
A new
equitable access agreement between Gavi, UNICEF and Bharat Biotech
(BBIL), announced(6) in October 2026
for the GSK-developed malaria vaccine, RTS,S/AS01, will cut the
price of the vaccine by 40%, generating around $50 million in
savings to child immunisation programmes (2027-29), and support
vaccination of an estimated 1 million more children. The agreement
follows investment by GSK and BBIL in new, higher-output
manufacturing facilities, product development and technology
transfer to expand and strengthen supply at a lower
cost.
|
Environment
|
|
|
|
●
|
All
five of GSK’s manufacturing sites in areas experiencing
water-stress across India, Pakistan and Algeria have now achieved
Alliance for Water Stewardship (AWS) certification, following a
rigorous independent audit. This certification recognises the work
our sites are doing to manage water responsibly, from how we use
water in our operations to how we understand and address water
risks in the communities where we operate.
|
|
●
|
In
September, GSK announced(7) a new eight-year
investment in regenerative agriculture carbon credits in northern
India. This agreement with Earthly aims to deliver both emissions
reductions and carbon removals, whilst delivering wider health and
local community benefits. The investment supports GSK’s
pathway to net zero impact on climate. By 2030, GSK aims to reduce
its carbon emissions by 80% (from a 2020 baseline), with the
remaining 20% covered through investment in high-quality nature
protection and restoration projects.
|
Responsible Business rating performance
Detailed
below is how GSK performs in key Responsible Business
ratings*.
|
|
|
|
|
|
External
benchmark
|
Current
score/ranking
|
Previous
score/ranking
|
Comments
|
|
Access
to Medicines Index
|
3.72
|
4.06
|
Second
in the Index, updated bi-annually, current results from November
2024. Scores range from 1 to 5, with 5 being the highest (best)
score
|
|
Antimicrobial
resistance benchmark
|
77%
|
84%
|
Led the
benchmark since its inception in 2018; Current ranking updated
March 2026
|
|
CDP
Climate Change
|
A
|
A
|
Updated
annually, current scores updated December 2025 (for supplier
engagement, May 2026)
|
|
CDP
Water Security
|
A
|
A
|
|
|
CDP
supplier engagement rating
|
Leader
|
Leader
|
|
|
Sustainalytics
|
Low
risk
|
Low
risk
|
2nd
percentile in pharma subindustry group. Current rating as at
October 2026
|
|
ISS
Corporate Rating
|
B+
|
B+
|
Ranked
1st in our peer group. Last profile update July 2026
|
|
FTSE4Good
|
Member
|
Member
|
Member
since 2004, latest review in July 2026
|
*GSK’s
Responsible Business ratings are regularly reviewed to ensure the
external benchmarks listed remain high quality, appropriate and
relevant to investors. The outcome of these reviews may lead to
changes on which ratings are included in the table above –
last updated July 2026
|
|
|
|
(1)
|
https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2025
|
|
(2)
|
https://www.gsk.com/media/di5bk40q/responsible-business-report.pdf
|
|
(3)
|
https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2026/october/axmed-partner-to-expand-access-to-hiv-medicines/
|
|
(4)
|
https://www.chugai-pharm.co.jp/english/news/detail/20260818113000_1263.html
|
|
(5)
|
https://www.mmv.org/news-resources-search/new-malaria-drug-candidate-shows-early-promise-human-study
|
|
(6)
|
https://www.gavi.org/news/media-room/gavi-and-unicef-secure-lower-malaria-vaccine-price-saving-us-50-million-childhood
|
|
(7)
|
https://earthly.org/blog/gsk-investment-in-regenerative-agriculture-carbon-credits-reduce-greenhouse-gas-emissions-and-air-pollution-supporting-human-health
|
Total and Core results
Total
reported results represent the Group’s overall
performance.
GSK
uses a number of non-IFRS measures to report the performance of its
business. Core results and other non-IFRS measures may be
considered in addition to, but not as a substitute for, or superior
to, information presented in accordance with IFRS. Core results are
defined below and other non-IFRS measures are defined on pages 43
and 44.
GSK
believes that Core results, when considered together with Total
results, provide investors, analysts and other stakeholders with
helpful complementary information to understand better the
financial performance and position of the Group from period to
period, and allow the Group’s performance to be more easily
compared against the majority of its peer companies. These measures
are also used by management for planning and reporting purposes.
They may not be directly comparable with similarly described
measures used by other companies.
GSK
encourages investors and analysts not to rely on any single
financial measure but to review GSK’s quarterly results
announcements, including the financial statements and notes, in
their entirety.
GSK is
committed to continuously improving its financial reporting, in
line with evolving regulatory requirements and best practice. In
line with this practice, GSK expects to continue to review and
refine its reporting framework.
Core results exclude the following items in relation to our
operations from Total results, together with the tax effects of all
of these items:
|
|
|
|
|
●
|
amortisation
of intangible assets (excluding computer software and capitalised
development costs) to reflect the Group's performance excluding the
effect of acquisitions
|
|
|
●
|
impairment
of intangible assets (excluding computer software) and goodwill to
reflect the Group's performance excluding the effect of
acquisitions
|
|
|
●
|
major
restructuring and integration costs, which are:
|
|
|
–
|
cash
and non-cash costs such as impairment of tangible assets and
computer software, relating to Major restructuring programmes which
are specific Board-approved programmes that are structural and of
significant scale, where the costs of individual or related
projects within such programmes exceed £25 million;
or
|
|
|
–
|
costs
that relate to restructuring and integration following a
significant acquisition.
|
|
|
Costs
for other ordinary course, smaller-scale restructuring and
integration are retained within both Total and Core
results
|
||
|
●
|
transaction-related
accounting or other adjustments related to significant
acquisitions
|
|
|
●
|
proceeds
and costs of disposal of associates, products and businesses;
significant settlement income; Significant legal charges (net of
insurance recoveries) and expenses on the settlement of litigation
and government investigations; other operating income other than
royalty income, and other items including amounts reclassified from
the foreign currency translation reserve to the income statement
upon the liquidation of a subsidiary where the amount exceeds
£25 million
|
|
As Core
results include the benefits of Major restructuring programmes but
exclude significant costs (such as Significant legal charges and
expenses, major restructuring costs and transaction items) they
should not be regarded as a complete picture of the Group’s
financial performance, which is presented in Total results. The
exclusion of other Adjusting items may result in Core earnings
being materially higher or lower than Total earnings. In
particular, when significant impairments, restructuring charges and
legal costs are excluded, Core earnings will be higher than Total
earnings.
GSK has
undertaken a number of Major restructuring programmes in response
to significant changes in the Group’s trading environment or
overall strategy or following material acquisitions. Within the
Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete. Costs, both cash and
non-cash, of these programmes are provided for as individual
elements are approved and meet the accounting recognition criteria.
As a result, charges may be incurred over a number of years
following the initiation of a Major restructuring
programme.
Significant
legal charges and expenses are those arising from the settlement of
litigation or government investigations that are not in the normal
course and materially larger than more regularly occurring
individual matters. They also include certain major legacy
matters.
Reconciliations
between Total and Core results, providing further information on
the key Adjusting items, are set out on pages 16 and
18.
GSK
provides earnings guidance to the investor community on the basis
of Core results. This is in line with peer companies and
expectations of the investor community, supporting easier
comparison of the Group’s performance with its peers. GSK is
not able to give guidance for Total results as it cannot reliably
forecast certain material elements of the Total results,
particularly the future fair value movements on contingent
consideration and put options that can and have given rise to
significant adjustments driven by external factors such as currency
and other movements in capital markets.
ViiV Healthcare
ViiV
Healthcare is a subsidiary of the Group and 100% of its operating
results (turnover, operating profit, profit after tax) are included
within the Group income statement.
On 19
January 2026, GSK reached agreement with Pfizer and Shionogi for
the 11.7% economic interest in ViiV Healthcare held by Pfizer to be
replaced with an investment by Shionogi. On 31 March 2026, the
transaction completed and Shionogi increased its economic interest
to 21.7% and GSK maintained its 78.3% economic interest. ViiV
Healthcare issued new shares to Shionogi for consideration of
$2.125 billion, and cancelled Pfizer’s holding in ViiV
Healthcare, returning $1.875 billion to Pfizer. GSK received a
special dividend of $0.250 billion (£187 million). Further, on
completion GSK extinguished the Pfizer put option liability through
retained earnings. The put option liability was £822 million
as at 31 December 2025 and was remeasured immediately prior to
completion, on the same methodology as at 31 December 2025, with
the £33 million change in the liability recognised as an
Adjusting item through other operating
income/(expense).
Earnings
for the year are allocated to the two shareholders of ViiV
Healthcare on the basis of their respective equity shareholdings
(GSK 78.3% and Shionogi 21.7%) and their entitlement to
preferential dividends, which are determined by the performance of
certain products attributable to each shareholder. As the relative
performance of these products changes over time, the proportion of
the overall earnings allocated to each shareholder also changes. In
particular, the increasing proportion of sales of dolutegravir and
cabotegravir-containing products has a favourable impact on the
proportion of the preferential dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity
interests. GSK was entitled to approximately 83% of the Total
earnings and 83% of the Core earnings of ViiV Healthcare for
2025.
As
consideration for the acquisition of Shionogi’s interest in
the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi
received the 10% equity stake in ViiV Healthcare and ViiV
Healthcare also agreed to pay additional future cash consideration
to Shionogi, contingent on the future sales performance of the
products being developed by that joint venture, dolutegravir and
cabotegravir. Under IFRS 3 ‘Business combinations’, GSK
was required to provide for the estimated fair value of this
contingent consideration at the time of acquisition and is required
to update the liability to the latest estimate of fair value at
each subsequent period end. The liability for the contingent
consideration recognised in the balance sheet at the date of
acquisition was £659 million. Subsequent remeasurements are
reflected within other operating income/(expense) and within
Adjusting items in the income statement in each
period.
Cash
payments to settle the contingent consideration are made to
Shionogi by ViiV Healthcare each quarter, based on the actual sales
performance and other income of the relevant products in the
previous quarter. These payments reduce the balance sheet liability
and hence are not recorded in the income statement. The cash
payments made to Shionogi by ViiV Healthcare in the nine months
ended 30 September 2026 were £1,052 million.
As the
liability is required to be recorded at the fair value of estimated
future payments, there is a significant timing difference between
the charges that are recorded in the Total income statement to
reflect movements in the fair value of the liability and the actual
cash payments made to settle the liability.
Further
explanation of the acquisition-related arrangements with ViiV
Healthcare is set out on pages 86 and 87 of the Annual Report
2025.
The
reconciliations between Total results and Core results for Q3 2026
and Q3 2025 are set out below.
Three months ended 30 September 2026
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
Intangible
asset
amort-
isation
£m
|
Intangible
asset
impair-
ment
£m
|
Major
restruc-
turing
and
integration
£m
|
Trans-
action-
related
£m
|
Divest-ments,
Significant
legal
and
other
items
£m
|
Core
results
£m
|
|
Turnover
|
8,887
|
|
|
|
|
|
8,887
|
|
Cost of
sales
|
(2,390)
|
190
|
|
150
|
|
10
|
(2,040)
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
6,497
|
190
|
|
150
|
|
10
|
6,847
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,383)
|
|
|
149
|
60
|
19
|
(2,155)
|
|
Research
and development
|
(1,983)
|
30
|
33
|
46
|
|
|
(1,874)
|
|
Royalty
income
|
258
|
|
|
|
|
|
258
|
|
Other
operating income/(expense)
|
(262)
|
|
|
|
289
|
(27)
|
–
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
2,127
|
220
|
33
|
345
|
349
|
2
|
3,076
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(190)
|
|
|
|
|
(7)
|
(197)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(2)
|
|
|
|
|
|
(2)
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
1,935
|
220
|
33
|
345
|
349
|
(5)
|
2,877
|
|
Taxation
|
(232)
|
(48)
|
(7)
|
(56)
|
(89)
|
(58)
|
(490)
|
|
Tax rate %
|
12.0%
|
|
|
|
|
|
17.0%
|
|
Profit after taxation
|
1,703
|
172
|
26
|
289
|
260
|
(63)
|
2,387
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
160
|
|
|
|
38
|
|
198
|
|
Profit/(loss)
attributable to shareholders
|
1,543
|
172
|
26
|
289
|
222
|
(63)
|
2,189
|
|
|
1,703
|
172
|
26
|
289
|
260
|
(63)
|
2,387
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
38.5p
|
4.3p
|
0.7p
|
7.2p
|
5.5p
|
(1.6p)
|
54.6p
|
|
Weighted average
number of shares (millions)
|
4,009
|
|
|
|
|
|
4,009
|
Three months ended 30 September 2025
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
Intangible
asset
amort-
isation
£m
|
Intangible
asset
impair-
ment
£m
|
Major
restruc-
turing
and
integration
£m
|
Trans-
action-
related
£m
|
Divest-ments,
Significant
legal
and
other
items
£m
|
Core
results
£m
|
|
Turnover
|
8,547
|
|
|
|
|
|
8,547
|
|
Cost of
sales
|
(2,258)
|
175
|
|
19
|
|
5
|
(2,059)
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
6,289
|
175
|
|
19
|
|
5
|
6,488
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,239)
|
|
|
38
|
39
|
3
|
(2,159)
|
|
Research
and development
|
(1,689)
|
23
|
112
|
2
|
|
|
(1,552)
|
|
Royalty
income
|
208
|
|
|
|
|
|
208
|
|
Other
operating income/(expense)
|
24
|
|
|
(1)
|
280
|
(303)
|
–
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
2,593
|
198
|
112
|
58
|
319
|
(295)
|
2,985
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(141)
|
|
|
|
|
9
|
(132)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
4
|
|
|
|
|
(9)
|
(5)
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
2,456
|
198
|
112
|
58
|
319
|
(295)
|
2,848
|
|
Taxation
|
(312)
|
(29)
|
(28)
|
(14)
|
(76)
|
4
|
(455)
|
|
Tax rate %
|
12.7%
|
|
|
|
|
|
16.0%
|
|
Profit after taxation
|
2,144
|
169
|
84
|
44
|
243
|
(291)
|
2,393
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
131
|
|
|
|
45
|
|
176
|
|
Profit/(loss)
attributable to shareholders
|
2,013
|
169
|
84
|
44
|
198
|
(291)
|
2,217
|
|
|
2,144
|
169
|
84
|
44
|
243
|
(291)
|
2,393
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
49.9p
|
4.2p
|
2.1p
|
1.1p
|
4.9p
|
(7.2p)
|
55.0p
|
|
Weighted average
number of shares (millions)
|
4,034
|
|
|
|
|
|
4,034
|
Adjusting items Q3 2026
Intangible asset impairments
There
were no significant intangible asset impairments in the
quarter.
Major restructuring and integration
Charges
of £345 million (Q3 2025: £58 million) were incurred
relating to ongoing projects categorised as Major restructuring
programmes and integration costs, analysed as follows:
|
|
|
|
|
|
|
|
|
|
Q3 2026
|
Q3
2025
|
||||
|
|
Cash
£m
|
Non-
cash
£m
|
Total
£m
|
Cash
£m
|
Non-
cash
£m
|
Total
£m
|
|
|
|
|
|
|
|
|
|
Accelerate
Growth programme
|
318
|
10
|
328
|
–
|
–
|
–
|
|
Significant
acquisitions
|
15
|
–
|
15
|
4
|
–
|
4
|
|
Legacy
programmes
|
1
|
1
|
2
|
50
|
4
|
54
|
|
|
334
|
11
|
345
|
54
|
4
|
58
|
Accelerate Growth programme
To
accelerate R&D and capture the growth and value the late-stage
portfolio offers, in Q3 2026 GSK initiated a new “Accelerate
Growth” programme. This 3-year programme has two
objectives:
|
(1)
|
Simplify,
and match GSK’s organisation and cost base to its evolving
product portfolio, notably in Specialty Medicines
|
|
(2)
|
Enable
the reallocation of GSK’s capital and resources to the
late-stage pipeline and to R&D.
|
The
Accelerate Growth programme is targeting £1.9 billion of
annual savings, to be fully realised by 2029, for expected total
costs of £2.4 billion, of which £2.1 billion is expected
to be cash costs. Savings will be primarily reinvested in R&D,
including business development activity, with a portion also used
to strengthen operating margin in the period related to LoE for
dolutegravir (2028-2030). The majority of the cost charges will be
in 2026 and 2027.
Integration
costs of significant acquisitions relate predominantly to
integration activities for Nuvalent Inc. acquired in Q3 2026 and
RAPT acquired in Q1 2026, with smaller incremental costs attributed
to earlier acquisitions.
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £349 million (Q3 2025:
£319 million), the majority of which related to
charges/(credits) for the remeasurement of contingent consideration
liabilities.
|
|
|
|
|
Charge/(credit)
|
Q3 2026
£m
|
Q3
2025
£m
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
venture
(including Shionogi preferential dividends)
|
240
|
249
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
–
|
(7)
|
|
Contingent
consideration on former Novartis Vaccines business
|
28
|
25
|
|
Contingent
consideration on acquisition of Affinivax
|
5
|
10
|
|
Other
contingent consideration
|
16
|
3
|
|
Other
adjustments
|
60
|
39
|
|
Total
transaction-related charges/(credits)
|
349
|
319
|
The
£240 million charge relating to the contingent consideration
for the former Shionogi-ViiV Healthcare joint venture represented
an increase in the valuation of the contingent consideration due to
Shionogi driven by updated sales forecasts and net other
remeasurements of £144 million and the unwind of the discount
for £96 million.
Other
adjustments of £60 million primarily related to Nuvalent
transaction costs.
Divestments, Significant legal charges, and other
items
Divestments,
Significant legal charges, and other items included net other
operating income of £27 million (Q3 2025: £303 million).
Q3 2025 included the £268 million ($370 million) settlement
from CureVac.
Legal
charges provide for all significant legal matters and are not
broken out separately by litigation or investigation.
The
reconciliations between Total results and Core results for 9 months
2026 and 9 months 2025 are set out below.
Nine months ended 30 September 2026
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
Intangible
asset
amort-
isation
£m
|
Intangible
asset
impair-
ment
£m
|
Major
restruc-
turing
and
integration
£m
|
Trans-
action-
related
£m
|
Divest-ments,
Significant
legal
and
other
items
£m
|
Core
results
£m
|
|
Turnover
|
24,925
|
|
|
|
|
|
24,925
|
|
Cost of
sales
|
(6,531)
|
524
|
190
|
156
|
|
22
|
(5,639)
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
18,394
|
524
|
190
|
156
|
|
22
|
19,286
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(6,704)
|
|
|
174
|
79
|
122
|
(6,329)
|
|
Research
and development
|
(7,141)
|
81
|
1,910
|
62
|
|
|
(5,088)
|
|
Royalty
income
|
657
|
|
|
|
|
|
657
|
|
Other
operating income/(expense)
|
(305)
|
|
|
|
1,040
|
(735)
|
–
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
4,901
|
605
|
2,100
|
392
|
1,119
|
(591)
|
8,526
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(459)
|
|
|
|
|
(2)
|
(461)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(9)
|
|
|
|
|
|
(9)
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
4,433
|
605
|
2,100
|
392
|
1,119
|
(593)
|
8,056
|
|
Taxation
|
pecialty
Medicines Total (338) |
(131)
|
(502)
|
(66)
|
(290)
|
(78)
|
(1,405)
|
|
Tax rate %
|
7.6%
|
|
|
|
|
|
17.4%
|
|
Profit after taxation
|
4,095
|
474
|
1,598
|
326
|
829
|
(671)
|
6,651
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
380
|
|
|
|
182
|
|
562
|
|
Profit/(loss)
attributable to shareholders
|
3,715
|
474
|
1,598
|
326
|
647
|
(671)
|
6,089
|
|
|
4,095
|
474
|
1,598
|
326
|
829
|
(671)
|
6,651
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
92.5p
|
11.8p
|
39.8p
|
8.1p
|
16.1p
|
(16.7p)
|
151.6p
|
|
Weighted average
number of shares (millions)
|
4,015
|
|
|
|
|
|
4,015
|
Nine months ended 30 September 2025
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
Intangible
asset
amort-
isation
£m
|
Intangible
asset
impair-
ment
£m
|
Major
restruc-
turing
and
integration
£m
|
Trans-
action-
related
£m
|
Divest-ments,
Significant
legal
and
other
items
£m
|
Core
results
£m
|
|
Turnover
|
24,049
|
|
|
|
|
|
24,049
|
|
Cost of
sales
|
(6,360)
|
546
|
|
30
|
|
13
|
(5,771)
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
17,689
|
546
|
|
30
|
|
13
|
18,278
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(6,449)
|
|
|
54
|
48
|
35
|
(6,312)
|
|
Research
and development
|
(5,175)
|
65
|
652
|
7
|
|
|
(4,451)
|
|
Royalty
income
|
634
|
|
|
|
|
|
634
|
|
Other
operating income/(expense)
|
133
|
|
|
|
193
|
(326)
|
–
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
6,832
|
611
|
652
|
91
|
241
|
(278)
|
8,149
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(383)
|
|
|
|
|
25
|
(358)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
2
|
|
|
|
|
(9)
|
(7)
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
6,451
|
611
|
652
|
91
|
241
|
(262)
|
7,784
|
|
Taxation
|
(889)
|
(134)
|
(163)
|
(22)
|
(134)
|
14
|
(1,328)
|
|
Tax rate %
|
13.8%
|
|
|
|
|
|
17.1%
|
|
Profit after taxation
|
5,562
|
477
|
489
|
69
|
107
|
(248)
|
6,456
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
482
|
|
|
|
31
|
|
513
|
|
Profit/(loss)
attributable to shareholders
|
5,080
|
477
|
489
|
69
|
76
|
(248)
|
5,943
|
|
|
5,562
|
477
|
489
|
69
|
107
|
(248)
|
6,456
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
125.1p
|
11.7p
|
12.0p
|
1.7p
|
1.9p
|
(6.1p)
|
146.3p
|
|
Weighted average
number of shares (millions)
|
4,062
|
|
|
|
|
|
4,062
|
Adjusting items 9 months 2026
Intangible asset impairments
YTD
2026 impairments of £2,100 million (YTD 2025: £652
million) primarily related to camlipixant £1,334 million in Q2
2026 following GSK's decision not to progress further development
of camlipixant in RCC, based on the aggregate data from the CALM-1
and CALM-2 phase III trials. In addition, a full impairment of
£371 million was recognised in Q2 2026 following the
termination of assets under the Alector collaboration, driven by
the outcome of clinical trials.
Major restructuring and integration
Charges
of £392 million (YTD 2025: £91 million) were incurred
relating to ongoing projects categorised as Major restructuring
programmes, analysed as follows:
|
|
|
|
|
|
|
|
|
|
9 months 2026
|
9
months 2025
|
||||
|
|
Cash
£m
|
Non-
cash
£m
|
Total
£m
|
Cash
£m
|
Non-
cash
£m
|
Total
£m
|
|
|
|
|
|
|
|
|
|
Accelerate
Growth programme
|
318
|
10
|
328
|
–
|
–
|
–
|
|
Significant
acquisitions
|
59
|
–
|
59
|
12
|
–
|
12
|
|
Legacy
programmes
|
3
|
2
|
5
|
60
|
19
|
79
|
|
|
380
|
12
|
392
|
72
|
19
|
91
|
Details
of the Accelerate Growth programme are provided on page
17.
The
Significant acquisitions programme incurred cash charges of
£59 million primarily from integration activities for Nuvalent
Inc. acquired in Q3 2026 and RAPT acquired in Q1 2026, with smaller
incremental costs attributed to earlier acquisitions.
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £1,119 million (9
months 2025: £241 million), the majority of which related to
charges/(credits) for the remeasurement of contingent consideration
liabilities.
|
|
|
|
|
Charge/(credit)
|
9 months 2026
£m
|
9
months 2025
£m
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
venture
(including Shionogi preferential dividends)
|
920
|
161
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
(33)
|
(96)
|
|
Contingent
consideration on former Novartis Vaccines business
|
28
|
134
|
|
Contingent
consideration on acquisition of Affinivax
|
12
|
(16)
|
|
Other
contingent consideration
|
113
|
10
|
|
Other
adjustments
|
79
|
48
|
|
Total
transaction-related charges
|
1,119
|
241
|
The
£920 million charge relating to the contingent consideration
for the former Shionogi-ViiV Healthcare joint venture represented
an increase in the valuation of the contingent consideration due to
Shionogi, driven by updated sales forecasts and net other
remeasurements of £631 million and the unwind of the discount
for £289 million.
Other
adjustments of £79 million primarily related to Nuvalent
transaction costs in Q3 2026.
Divestments, Significant legal charges, and other
items
Divestments,
Significant legal charges, and other items included net other
operating income of £735 million (YTD 2025: £326 million)
primarily related to profit on the sale of the Rockville
manufacturing facility, including £375m reclassified from the
foreign currency translation reserve to the income statement on
disposal of the related subsidiary, and proceeds from the
divestment of linerixibat. This was partly offset by amounts
reclassified from the foreign currency translation reserve to the
income statement upon the liquidation of subsidiaries. YTD 2025
included the £268 million ($370 million) settlement from
CureVac.
Legal
charges provide for all significant legal matters and are not
broken out separately by litigation or investigation.
Financial information
Income statement
|
|
|
|
|
|
|
|
Q3 2026
£m
|
Q3
2025
£m
|
9 months 2026
£m
|
9
months 2025
£m
|
|
|
|
|
|
|
|
TURNOVER
|
8,887
|
8,547
|
24,925
|
24,049
|
|
Cost of
sales
|
(2,390)
|
(2,258)
|
(6,531)
|
(6,360)
|
|
Gross
profit
|
6,497
|
6,289
|
18,394
|
17,689
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,383)
|
(2,239)
|
(6,704)
|
(6,449)
|
|
Research
and development
|
(1,983)
|
(1,689)
|
(7,141)
|
(5,175)
|
|
Royalty
income
|
258
|
208
|
657
|
634
|
|
Other
operating income/(expense)
|
(262)
|
24
|
(305)
|
133
|
|
|
|
|
|
|
|
OPERATING PROFIT
|
2,127
|
2,593
|
4,901
|
6,832
|
|
|
|
|
|
|
|
Finance
income
|
29
|
26
|
109
|
130
|
|
Finance
expense
|
(219)
|
(167)
|
(568)
|
(513)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(2)
|
4
|
(9)
|
2
|
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION
|
1,935
|
2,456
|
4,433
|
6,451
|
|
Taxation
|
(232)
|
(312)
|
(338)
|
(889)
|
|
Tax rate %
|
12.0%
|
12.7%
|
7.6%
|
13.8%
|
|
PROFIT AFTER TAXATION
|
1,703
|
2,144
|
4,095
|
5,562
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
160
|
131
|
380
|
482
|
|
Profit
attributable to shareholders
|
1,543
|
2,013
|
3,715
|
5,080
|
|
|
1,703
|
2,144
|
4,095
|
5,562
|
|
|
|
|
|
|
|
EARNINGS PER SHARE
|
38.5p
|
49.9p
|
92.5p
|
125.1p
|
|
Diluted
earnings per share
|
37.9p
|
49.1p
|
91.1p
|
123.0p
|
Statement of comprehensive income
|
|
|
|
|
|
|
|
Q3 2026
£m
|
Q3
2025
£m
|
9 months 2026
£m
|
9
months 2025
£m
|
|
|
|
|
|
|
|
Total
profit for the period
|
1,703
|
2,144
|
4,095
|
5,562
|
|
|
|
|
|
|
|
Items
that may be reclassified subsequently to income
statement:
|
|
|
|
|
|
Exchange movements
on overseas net assets and net investment hedges
|
(21)
|
25
|
(103)
|
292
|
|
Reclassification of
exchange movements on liquidation or disposal of overseas
subsidiaries and associates
|
–
|
(1)
|
(266)
|
(9)
|
|
Fair
value movements on cash flow hedges
|
135
|
23
|
173
|
(33)
|
|
Cost of
hedging
|
3
|
3
|
–
|
12
|
|
Reclassification
of cash flow hedges to income statement
|
12
|
(19)
|
(3)
|
29
|
|
Deferred
tax on fair value movements on cash flow hedges
|
(7)
|
(1)
|
(8)
|
(1)
|
|
|
122
|
30
|
(207)
|
290
|
|
Items that will not be reclassified to income
statement:
|
|
|
|
|
|
Exchange movements
on overseas net assets of non-controlling interests
|
(2)
|
9
|
1
|
(14)
|
|
Share
of the other comprehensive income of associates and joint
ventures
|
4
|
–
|
48
|
–
|
|
Fair
value movements on equity investments
|
2
|
115
|
(54)
|
81
|
|
Tax on
fair value movements on equity investments
|
1
|
(10)
|
(1)
|
(14)
|
|
Fair
value movements on cash flow hedges
|
4
|
–
|
8
|
–
|
|
Remeasurement
gains/(losses) on defined benefit plans
|
40
|
58
|
407
|
132
|
|
Tax
(charge)/credit on remeasurement of defined benefit
plans
|
(8)
|
(15)
|
(97)
|
(31)
|
|
|
41
|
157
|
312
|
154
|
|
Other
comprehensive income/(expense) for the period
|
163
|
187
|
105
|
444
|
|
Total
comprehensive income for the period
|
1,866
|
2,331
|
4,200
|
6,006
|
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
|
Shareholders
|
1,708
|
2,191
|
3,819
|
5,538
|
|
Non-controlling interests
|
158
|
140
|
381
|
468
|
|
|
1,866
|
2,331
|
4,200
|
6,006
|
Balance sheet
|
|
|
|
|
|
30 September 2026
£m
|
31
December 2025
£m
|
|
ASSETS
|
|
|
|
Non-current assets
|
|
|
|
Property,
plant and equipment
|
9,431
|
9,322
|
|
Right
of use assets
|
691
|
726
|
|
Goodwill
|
8,216
|
7,018
|
|
Other
intangible assets
|
25,172
|
16,748
|
|
Investments
in associates and joint ventures
|
49
|
89
|
|
Other
investments
|
814
|
1,037
|
|
Deferred
tax assets
|
6,735
|
6,520
|
|
Derivative
financial instruments
|
54
|
–
|
|
Other
non-current assets
|
2,642
|
2,148
|
|
Total non-current assets
|
53,804
|
43,608
|
|
Current assets
|
|
|
|
Inventories
|
6,300
|
5,924
|
|
Current
tax recoverable
|
302
|
288
|
|
Trade
and other receivables
|
8,223
|
7,471
|
|
Derivative
financial instruments
|
103
|
121
|
|
Liquid
investments
|
28
|
9
|
|
Cash
and cash equivalents
|
2,934
|
3,397
|
|
Assets
held for sale
|
5
|
300
|
|
Total current assets
|
17,895
|
17,510
|
|
TOTAL ASSETS
|
71,699
|
61,118
|
|
|
|
|
|
LIABILITIES
|
|
|
|
Current liabilities
|
|
|
|
Short-term
borrowings
|
(2,001)
|
(3,012)
|
|
Contingent
consideration liabilities
|
(1,318)
|
(1,348)
|
|
Trade
and other payables
|
(15,633)
|
(15,381)
|
|
Derivative
financial instruments
|
(164)
|
(75)
|
|
Current
tax payable
|
(678)
|
(498)
|
|
Short-term
provisions
|
(926)
|
(938)
|
|
Liabilities
relating to assets held for sale
|
–
|
(139)
|
|
Total current liabilities
|
(20,720)
|
(21,391)
|
|
Non-current liabilities
|
|
|
|
Long-term
borrowings
|
(21,700)
|
(14,708)
|
|
Deferred
tax liabilities
|
(1,670)
|
(291)
|
|
Pensions
and other post-employment benefits
|
(1,552)
|
(1,687)
|
|
Derivative
financial instruments
|
(101)
|
(67)
|
|
Other
provisions
|
(751)
|
(610)
|
|
Contingent
consideration liabilities
|
(5,311)
|
(5,385)
|
|
Other
non-current liabilities
|
(1,532)
|
(1,023)
|
|
Total non-current liabilities
|
(32,617)
|
(23,771)
|
|
TOTAL LIABILITIES
|
(53,337)
|
(45,162)
|
|
|
|
|
|
NET ASSETS
|
18,362
|
15,956
|
|
|
|
|
|
EQUITY
|
|
|
|
Share
capital
|
1,349
|
1,349
|
|
Share
premium account
|
3,507
|
3,498
|
|
Retained
earnings
|
12,458
|
10,209
|
|
Other
reserves
|
1,440
|
1,321
|
|
Shareholders’ equity
|
18,754
|
16,377
|
|
Non-controlling
interests
|
(392)
|
(421)
|
|
TOTAL EQUITY
|
18,362
|
15,956
|
Statement of changes in equity
|
|
|
|
|
|
|
|
|
|||||||
|
|
Share
capital
£m
|
Share
premium
£m
|
Retained
earnings
£m
|
Other
reserves
£m
|
Share-
holder’s
equity
£m
|
Non-
controlling
interests
£m
|
Total
equity
£m
|
|||||||
|
At 1
January 2026
|
1,349
|
3,498
|
10,209
|
1,321
|
16,377
|
(421)
|
15,956
|
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
Profit
for the period
|
|
|
3,715
|
|
3,715
|
380
|
4,095
|
|||||||
|
Other comprehensive income/(expense) for the period
|
|
|
(55)
|
159
|
104
|
1
|
105
|
|||||||
|
Total
comprehensive income/(expense) for the period
|
|
|
3,660
|
159
|
3,819
|
381
|
4,200
|
|||||||
|
Dividend
distributions to non-controlling interests
|
|
|
|
|
|
(354)
|
(354)
|
|||||||
|
Derecognition of
liabilities with non-controlling interests
|
|
|
789
|
|
789
|
|
789
|
|||||||
|
Contributions
from non-controlling interests
|
|
|
187
|
|
187
|
1,399
|
1,586
|
|||||||
|
Other
distributions to non-controlling interests
|
|
|
|
|
|
(1,399)
|
(1,399)
|
|||||||
|
Dividends
to shareholders
|
|
|
(2,052)
|
|
(2,052)
|
|
(2,052)
|
|||||||
|
Realised after tax
profit/(losses) on disposal or liquidation of equity
investments
|
|
|
140
|
(140)
|
|
|
–
|
|||||||
|
Share
of associates and joint ventures realised profit/(loss) on disposal
of equity investments
|
|
|
63
|
(63)
|
|
|
–
|
|||||||
|
Shares
issued
|
|
9
|
|
|
9
|
|
9
|
|||||||
|
Purchase
of treasury shares
|
|
|
(634)
|
|
(634)
|
|
(634)
|
|||||||
|
Write-down
of shares held by ESOP Trusts
|
|
|
(171)
|
171
|
|
|
–
|
|||||||
|
Share-based
incentive plans
|
|
|
267
|
|
267
|
|
267
|
|||||||
|
Changes
to non-controlling interests
|
|
|
|
|
|
2
|
2
|
|||||||
|
Hedging
gain/loss after taxation transferred to non-financial
assets
|
|
|
|
(8)
|
(8)
|
|
(8)
|
|||||||
|
At 30 September 2026
|
1,349
|
3,507
|
12,458
|
1,440
|
18,754
|
(392)
|
18,362
|
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
|
Share
capital
£m
|
Share
premium
£m
|
Retained
earnings
£m
|
Other
reserves
£m
|
Share-
holder’s
equity
£m
|
Non-
controlling
interests
£m
|
Total
equity
£m
|
|||||||
|
At 1
January 2025
|
1,348
|
3,473
|
7,796
|
1,054
|
13,671
|
(585)
|
13,086
|
|||||||
|
|
|
|
|
|
|
|
|
|||||||
|
Profit
for the period
|
|
|
5,080
|
|
5,080
|
482
|
5,562
|
|||||||
|
Other comprehensive income/(expense) for the period
|
|
|
371
|
87
|
458
|
(14)
|
444
|
|||||||
|
Total
comprehensive income/(expense) for the period
|
|
|
5,451
|
87
|
5,538
|
468
|
6,006
|
|||||||
|
Dividend
distributions to non-controlling interests
|
|
|
|
|
|
(279)
|
(279)
|
|||||||
|
Dividends
to shareholders
|
|
|
(1,918)
|
|
(1,918)
|
|
(1,918)
|
|||||||
|
Realised after tax
profit/(losses) on disposal or liquidation of equity
investments
|
|
|
26
|
(26)
|
|
|
–
|
|||||||
|
Share
of associates and joint ventures realised profit/(loss) on disposal
of equity investments
|
|
|
(1)
|
1
|
|
|
–
|
|||||||
|
Shares
issued
|
1
|
13
|
|
|
14
|
|
14
|
|||||||
|
Purchase
of treasury shares(*)
|
|
|
(1,425)
|
|
(1,425)
|
|
(1,425)
|
|||||||
|
Write-down
of shares held by ESOP Trusts
|
|
|
(181)
|
181
|
|
|
–
|
|||||||
|
Share-based
incentive plans
|
|
|
268
|
|
268
|
|
268
|
|||||||
|
At 30
September 2025
|
1,349
|
3,486
|
10,016
|
1,297
|
16,148
|
(396)
|
15,752
|
|||||||
(*)
Included shares committed to repurchase under irrevocable contracts
and repurchases subject to settlement at the end of the
period.
Cash flow statement nine months ended 30 September
2026
|
|
|
|
|
|
9 months 2026
£m
|
9
months 2025
£m
|
|
|
|
|
|
Profit after tax
|
4,095
|
5,562
|
|
Tax on
profits
|
338
|
889
|
|
Share
of after tax loss/(profit) of associates and joint
ventures
|
9
|
(2)
|
|
Net
finance expense
|
459
|
383
|
|
Depreciation,
amortisation, impairments and other adjusting items
|
3,527
|
2,720
|
|
(Increase)/decrease
in working capital
|
(1,521)
|
(2,025)
|
|
Contingent
consideration paid
|
(1,095)
|
(989)
|
|
Increase/(decrease)
in other net liabilities (excluding contingent consideration
paid)
|
1,566
|
(284)
|
|
Cash generated from operations
|
7,378
|
6,254
|
|
Taxation
paid
|
(738)
|
(791)
|
|
Total net cash inflow/(outflow) from operating
activities
|
6,640
|
5,463
|
|
|
|
|
|
Cash flow from investing activities
|
|
|
|
Purchase
of property, plant and equipment
|
(923)
|
(775)
|
|
Proceeds
from sale of property, plant and equipment
|
33
|
11
|
|
Purchase
of intangible assets
|
(706)
|
(1,185)
|
|
Proceeds
from sale of intangible assets
|
356
|
112
|
|
Purchase
of equity investments
|
(43)
|
(52)
|
|
Proceeds
from sale of equity investments
|
219
|
138
|
|
Purchase
of businesses, net of cash acquired
|
(9,247)
|
(1,655)
|
|
Contingent
consideration paid
|
(96)
|
(11)
|
|
Disposal
of businesses
|
247
|
(28)
|
|
Interest
received
|
100
|
117
|
|
(Increase)/decrease
in liquid investments
|
(20)
|
11
|
|
Dividends
and distributions from joint ventures and associates
|
79
|
–
|
|
Dividend
and distributions from investments
|
38
|
17
|
|
Total net cash inflow/(outflow) from investing
activities
|
(9,963)
|
(3,300)
|
|
|
|
|
|
Cash flow from financing activities
|
|
|
|
Issue
of share capital
|
9
|
14
|
|
Repayment
of long-term loans
|
(1,466)
|
(1,402)
|
|
Issue
of long-term notes
|
7,779
|
1,979
|
|
Net
increase/(decrease) in short-term loans
|
(246)
|
551
|
|
Increase
in other short-term loans
|
11
|
112
|
|
Repayment
of other short-term loans
|
(106)
|
(282)
|
|
Repayment
of lease liabilities
|
(152)
|
(166)
|
|
Interest
paid
|
(431)
|
(384)
|
|
Dividends
paid to shareholders
|
(2,052)
|
(1,918)
|
|
Purchase
of treasury shares
|
(634)
|
(1,125)
|
|
Dividend
distributions to non-controlling interests
|
(354)
|
(279)
|
|
Other
distributions to non-controlling interests
|
(1,399)
|
–
|
|
Contributions
from non-controlling interests
|
1,588
|
–
|
|
Other
financing items
|
246
|
71
|
|
Total net cash inflow/(outflow) from financing
activities
|
2,793
|
(2,829)
|
|
|
|
|
|
Increase/(decrease) in cash and bank overdrafts in the
period
|
(530)
|
(666)
|
|
|
|
|
|
Cash
and bank overdrafts at beginning of the period
|
3,207
|
3,403
|
|
Adjustment
on initial application of amendments to IFRS 9 on 1 January
2026(1)
|
43
|
–
|
|
Cash
and bank overdrafts at beginning of the period, as
adjusted
|
3,250
|
3,403
|
|
Exchange
adjustments
|
(39)
|
22
|
|
Increase/(decrease)
in cash and bank overdrafts in the period
|
(530)
|
(666)
|
|
Cash and bank overdrafts at end of the period
|
2,681
|
2,759
|
|
|
|
|
|
Cash
and bank overdrafts at end of period comprise:
|
|
|
|
Cash and cash equivalents
|
2,934
|
3,296
|
|
Overdrafts
|
(253)
|
(537)
|
|
|
2,681
|
2,759
|
(1) For
further details see page 31
Sales tables
Specialty Medicines turnover – three months ended 30
September 2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
HIV
|
2,116
|
9
|
10
|
1,524
|
13
|
14
|
399
|
5
|
6
|
193
|
(11)
|
(11)
|
|
Dolutegravir
products
|
1,445
|
2
|
3
|
946
|
6
|
7
|
329
|
1
|
2
|
170
|
(14)
|
(15)
|
|
Dovato
|
754
|
8
|
9
|
443
|
12
|
13
|
221
|
8
|
9
|
90
|
(3)
|
(6)
|
|
Juluca
|
171
|
9
|
10
|
140
|
11
|
12
|
28
|
–
|
–
|
3
|
–
|
–
|
|
Tivicay
|
319
|
(3)
|
(2)
|
207
|
6
|
6
|
53
|
(9)
|
(7)
|
59
|
(22)
|
(20)
|
|
Triumeq
|
201
|
(15)
|
(14)
|
156
|
(11)
|
(10)
|
27
|
(21)
|
(21)
|
18
|
(31)
|
(31)
|
|
Long
Acting Injectables
|
621
|
30
|
31
|
538
|
31
|
32
|
63
|
24
|
24
|
20
|
33
|
40
|
|
Apretude
|
143
|
19
|
21
|
136
|
17
|
18
|
2
|
–
|
–
|
5
|
25
|
50
|
|
Cabenuva
|
478
|
34
|
35
|
402
|
36
|
38
|
61
|
20
|
20
|
15
|
36
|
36
|
|
Other
|
50
|
2
|
–
|
40
|
–
|
–
|
7
|
75
|
50
|
3
|
(40)
|
(40)
|
|
Respiratory,
Immunology & Inflammation
|
1,139
|
19
|
21
|
758
|
22
|
23
|
173
|
5
|
5
|
208
|
24
|
27
|
|
Benlysta
|
520
|
16
|
17
|
434
|
18
|
19
|
37
|
6
|
6
|
49
|
14
|
14
|
|
Exdensur
|
27
|
–
|
–
|
14
|
–
|
–
|
2
|
–
|
–
|
11
|
–
|
–
|
|
Nucala
|
582
|
17
|
18
|
310
|
23
|
24
|
136
|
2
|
3
|
136
|
19
|
21
|
|
Other
|
10
|
25
|
37
|
–
|
–
|
–
|
(2)
|
33
|
33
|
12
|
9
|
27
|
|
Oncology
|
622
|
22
|
23
|
392
|
12
|
13
|
154
|
26
|
26
|
76
|
90
|
93
|
|
Blenrep
|
50
|
–
|
–
|
25
|
–
|
–
|
15
|
–
|
–
|
10
|
–
|
–
|
|
Jemperli
|
273
|
19
|
19
|
191
|
12
|
13
|
57
|
30
|
30
|
25
|
67
|
60
|
|
Jideytro
|
3
|
–
|
–
|
3
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Ojjaara/Omjjara
|
195
|
34
|
35
|
129
|
23
|
25
|
40
|
43
|
43
|
26
|
100
|
100
|
|
Zejula
|
104
|
(24)
|
(23)
|
44
|
(40)
|
(38)
|
44
|
(14)
|
(12)
|
16
|
23
|
15
|
|
Other
|
(3)
|
(50)
|
(50)
|
–
|
–
|
–
|
(2)
|
>(100)
|
>(100)
|
(1)
|
–
|
–
|
|
Specialty Medicines
|
3,877
|
14
|
15
|
2,674
|
15
|
17
|
726
|
9
|
9
|
477
|
12
|
13
|
Specialty Medicines turnover – nine months ended 30 September
2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
HIV
|
6,018
|
9
|
10
|
4,203
|
12
|
14
|
1,205
|
6
|
4
|
610
|
(4)
|
(5)
|
|
Dolutegravir
products
|
4,181
|
2
|
3
|
2,622
|
3
|
6
|
1,011
|
4
|
2
|
548
|
(6)
|
(7)
|
|
Dovato
|
2,169
|
13
|
14
|
1,218
|
13
|
16
|
673
|
13
|
11
|
278
|
11
|
10
|
|
Juluca
|
487
|
3
|
5
|
393
|
4
|
7
|
86
|
(1)
|
(3)
|
8
|
(11)
|
–
|
|
Tivicay
|
948
|
(3)
|
(2)
|
581
|
3
|
5
|
165
|
(5)
|
(7)
|
202
|
(15)
|
(16)
|
|
Triumeq
|
577
|
(20)
|
(19)
|
430
|
(17)
|
(15)
|
87
|
(26)
|
(27)
|
60
|
(30)
|
(29)
|
|
Long
Acting Injectables
|
1,702
|
31
|
33
|
1,469
|
31
|
34
|
180
|
22
|
20
|
53
|
56
|
56
|
|
Apretude
|
403
|
30
|
33
|
387
|
27
|
31
|
4
|
–
|
–
|
12
|
>100
|
>100
|
|
Cabenuva
|
1,299
|
31
|
33
|
1,082
|
32
|
36
|
176
|
20
|
18
|
41
|
46
|
46
|
|
Other
|
135
|
(6)
|
(5)
|
112
|
2
|
5
|
14
|
8
|
(8)
|
9
|
(57)
|
(52)
|
|
Respiratory,
Immunology & Inflammation
|
3,164
|
16
|
18
|
2,064
|
18
|
21
|
519
|
11
|
8
|
581
|
16
|
20
|
|
Benlysta
|
1,402
|
12
|
14
|
1,147
|
12
|
15
|
112
|
14
|
11
|
143
|
7
|
10
|
|
Exdensur
|
56
|
–
|
–
|
33
|
–
|
–
|
4
|
–
|
–
|
19
|
–
|
–
|
|
Nucala
|
1,676
|
16
|
18
|
884
|
21
|
24
|
410
|
6
|
4
|
382
|
16
|
20
|
|
Other
|
30
|
29
|
42
|
–
|
–
|
–
|
(7)
|
49
|
49
|
37
|
–
|
11
|
|
Oncology
|
1,703
|
21
|
22
|
1,087
|
11
|
14
|
428
|
29
|
26
|
188
|
88
|
94
|
|
Blenrep
|
109
|
>100
|
>100
|
55
|
–
|
–
|
35
|
>100
|
>100
|
19
|
–
|
–
|
|
Jemperli
|
753
|
25
|
27
|
543
|
19
|
22
|
145
|
36
|
33
|
65
|
76
|
78
|
|
Jideytro
|
3
|
–
|
–
|
3
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Ojjaara/Omjjara
|
526
|
33
|
35
|
350
|
15
|
18
|
113
|
71
|
68
|
63
|
>100
|
>100
|
|
Zejula
|
319
|
(24)
|
(23)
|
136
|
(37)
|
(35)
|
141
|
(14)
|
(15)
|
42
|
8
|
8
|
|
Other
|
(7)
|
22
|
22
|
–
|
–
|
–
|
(6)
|
25
|
12
|
(1)
|
–
|
>100
|
|
Specialty Medicines
|
10,885
|
13
|
14
|
7,354
|
13
|
16
|
2,152
|
11
|
9
|
1,379
|
11
|
13
|
Vaccines turnover – three months ended 30 September
2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
Shingles
|
780
|
(6)
|
(5)
|
290
|
13
|
14
|
289
|
(3)
|
(1)
|
201
|
(27)
|
(26)
|
|
Shingrix
|
780
|
(6)
|
(5)
|
290
|
13
|
14
|
289
|
(3)
|
(1)
|
201
|
(27)
|
(26)
|
|
Meningitis
|
599
|
11
|
12
|
358
|
13
|
15
|
144
|
(6)
|
(5)
|
97
|
37
|
34
|
|
Bexsero
|
378
|
3
|
4
|
178
|
10
|
12
|
142
|
(6)
|
(5)
|
58
|
7
|
4
|
|
Menveo
|
189
|
13
|
14
|
150
|
1
|
2
|
2
|
–
|
–
|
37
|
>100
|
>100
|
|
Penmenvy
|
30
|
>100
|
>100
|
30
|
>100
|
>100
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Other
|
2
|
100
|
100
|
–
|
–
|
–
|
–
|
(100)
|
–
|
2
|
–
|
–
|
|
RSV
|
195
|
(22)
|
(24)
|
55
|
(61)
|
(60)
|
103
|
37
|
36
|
37
|
3
|
(6)
|
|
Arexvy
|
195
|
(22)
|
(24)
|
55
|
(61)
|
(60)
|
103
|
37
|
36
|
37
|
3
|
(6)
|
|
Influenza
|
177
|
(18)
|
(17)
|
125
|
(23)
|
(21)
|
17
|
(6)
|
(6)
|
35
|
–
|
–
|
|
Fluarix, FluLaval
|
177
|
(18)
|
(17)
|
125
|
(23)
|
(21)
|
17
|
(6)
|
(6)
|
35
|
–
|
–
|
|
Other
Paediatric & Adult Vaccines
|
832
|
(1)
|
–
|
438
|
13
|
14
|
182
|
1
|
(1)
|
212
|
(21)
|
(19)
|
|
Boostrix
|
211
|
16
|
17
|
146
|
20
|
20
|
36
|
–
|
3
|
29
|
21
|
21
|
|
Hepatitis
|
188
|
3
|
3
|
105
|
4
|
6
|
48
|
(11)
|
(13)
|
35
|
25
|
21
|
|
Infanrix, Pediarix
|
153
|
6
|
7
|
103
|
12
|
13
|
23
|
(15)
|
(15)
|
27
|
4
|
8
|
|
Priorix, Priorix Tetra, Varilrix
|
83
|
(43)
|
(42)
|
22
|
47
|
40
|
36
|
12
|
6
|
25
|
(75)
|
(71)
|
|
Rotarix
|
153
|
1
|
3
|
59
|
9
|
11
|
29
|
(12)
|
(12)
|
65
|
–
|
3
|
|
Other
|
44
|
37
|
50
|
3
|
(40)
|
20
|
10
|
>100
|
>100
|
31
|
11
|
14
|
|
Vaccines
|
2,583
|
(4)
|
(2)
|
1,266
|
–
|
2
|
735
|
1
|
2
|
582
|
(16)
|
(15)
|
Vaccines turnover – nine months ended 30 September
2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
Shingles
|
2,694
|
6
|
6
|
924
|
6
|
9
|
1,184
|
25
|
22
|
586
|
(20)
|
(17)
|
|
Shingrix
|
2,694
|
6
|
6
|
924
|
6
|
9
|
1,184
|
25
|
22
|
586
|
(20)
|
(17)
|
|
Meningitis
|
1,396
|
10
|
11
|
619
|
6
|
9
|
473
|
5
|
3
|
304
|
27
|
28
|
|
Bexsero
|
972
|
8
|
8
|
315
|
2
|
4
|
466
|
6
|
4
|
191
|
28
|
30
|
|
Menveo
|
352
|
1
|
3
|
257
|
(4)
|
(1)
|
6
|
–
|
–
|
89
|
17
|
17
|
|
Penmenvy
|
47
|
>100
|
>100
|
47
|
>100
|
>100
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Other
|
25
|
56
|
50
|
–
|
–
|
–
|
1
|
(50)
|
(50)
|
24
|
71
|
64
|
|
RSV
|
452
|
14
|
12
|
138
|
(40)
|
(38)
|
176
|
57
|
54
|
138
|
>100
|
>100
|
|
Arexvy
|
452
|
14
|
12
|
138
|
(40)
|
(38)
|
176
|
57
|
54
|
138
|
>100
|
>100
|
|
Influenza
|
198
|
(11)
|
(9)
|
129
|
(19)
|
(17)
|
18
|
–
|
–
|
51
|
11
|
13
|
|
Fluarix, FluLaval
|
198
|
(11)
|
(9)
|
129
|
(19)
|
(17)
|
18
|
–
|
–
|
51
|
11
|
13
|
|
Other
Paediatric & Adult Vaccines
|
2,276
|
(6)
|
(5)
|
1,050
|
2
|
5
|
559
|
8
|
5
|
667
|
(24)
|
(23)
|
|
Boostrix
|
551
|
9
|
11
|
359
|
15
|
18
|
112
|
2
|
–
|
80
|
(2)
|
(4)
|
|
Hepatitis
|
496
|
(2)
|
(2)
|
246
|
(9)
|
(6)
|
152
|
1
|
(1)
|
98
|
13
|
11
|
|
Infanrix, Pediarix
|
384
|
(7)
|
(6)
|
228
|
(6)
|
(3)
|
83
|
1
|
(1)
|
73
|
(20)
|
(18)
|
|
Priorix, Priorix Tetra, Varilrix
|
246
|
(25)
|
(24)
|
54
|
12
|
15
|
103
|
14
|
11
|
89
|
(53)
|
(51)
|
|
Rotarix
|
419
|
(2)
|
–
|
151
|
10
|
13
|
88
|
(4)
|
(7)
|
180
|
(9)
|
(7)
|
|
Other
|
180
|
(27)
|
(27)
|
12
|
(37)
|
(37)
|
21
|
>100
|
>100
|
147
|
(37)
|
(36)
|
|
Vaccines
|
7,016
|
2
|
3
|
2,860
|
–
|
2
|
2,410
|
18
|
15
|
1,746
|
(11)
|
(9)
|
General Medicines turnover – three months ended 30 September
2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
Respiratory
|
1,708
|
–
|
1
|
946
|
3
|
4
|
316
|
(7)
|
(6)
|
446
|
–
|
1
|
|
Anoro Ellipta
|
138
|
1
|
1
|
49
|
(4)
|
(2)
|
62
|
3
|
2
|
27
|
4
|
4
|
|
Flixotide/Flovent
|
73
|
(26)
|
(24)
|
47
|
(28)
|
(29)
|
11
|
(21)
|
(21)
|
15
|
(21)
|
(11)
|
|
Relvar/Breo Ellipta
|
221
|
(14)
|
(12)
|
76
|
(22)
|
(22)
|
76
|
(13)
|
(13)
|
69
|
(4)
|
–
|
|
Seretide/Advair
|
191
|
(4)
|
(4)
|
66
|
8
|
10
|
34
|
(23)
|
(20)
|
91
|
(3)
|
(4)
|
|
Trelegy Ellipta
|
787
|
7
|
8
|
572
|
7
|
8
|
88
|
5
|
5
|
127
|
9
|
11
|
|
Ventolin
|
181
|
16
|
17
|
108
|
40
|
40
|
26
|
(4)
|
–
|
47
|
(10)
|
(10)
|
|
Other
Respiratory
|
117
|
(3)
|
(1)
|
28
|
(10)
|
–
|
19
|
(17)
|
(9)
|
70
|
6
|
2
|
|
Other
General Medicines
|
719
|
(5)
|
(3)
|
45
|
(12)
|
(12)
|
151
|
3
|
4
|
523
|
(7)
|
(4)
|
|
Blujepa
|
1
|
–
|
–
|
1
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Other
General Medicines
|
718
|
(5)
|
(3)
|
44
|
(14)
|
(14)
|
151
|
3
|
4
|
523
|
(7)
|
(4)
|
|
General Medicines
|
2,427
|
(1)
|
–
|
991
|
2
|
3
|
467
|
(4)
|
(3)
|
969
|
(4)
|
(2)
|
General Medicines turnover – nine months ended 30 September
2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
Respiratory
|
4,981
|
(6)
|
(4)
|
2,634
|
(9)
|
(6)
|
1,012
|
(2)
|
(4)
|
1,335
|
(2)
|
–
|
|
Anoro Ellipta
|
405
|
(1)
|
(1)
|
137
|
(16)
|
(13)
|
191
|
10
|
8
|
77
|
4
|
4
|
|
Flixotide/Flovent
|
291
|
(6)
|
(4)
|
197
|
(2)
|
–
|
41
|
(13)
|
(15)
|
53
|
(13)
|
(10)
|
|
Relvar/Breo Ellipta
|
682
|
(13)
|
(12)
|
228
|
(25)
|
(23)
|
243
|
(9)
|
(11)
|
211
|
(3)
|
1
|
|
Seretide/Advair
|
574
|
(7)
|
(6)
|
187
|
5
|
8
|
121
|
(13)
|
(14)
|
266
|
(11)
|
(10)
|
|
Trelegy Ellipta
|
2,208
|
(2)
|
–
|
1,570
|
(5)
|
(3)
|
265
|
7
|
5
|
373
|
9
|
12
|
|
Ventolin
|
455
|
(10)
|
(9)
|
229
|
(14)
|
(12)
|
80
|
(7)
|
(8)
|
146
|
(6)
|
(5)
|
|
Other
Respiratory
|
366
|
(11)
|
(10)
|
86
|
(27)
|
(24)
|
71
|
(10)
|
(11)
|
209
|
(1)
|
(2)
|
|
Other
General Medicines
|
2,043
|
(9)
|
(6)
|
128
|
(22)
|
(21)
|
479
|
7
|
4
|
1,436
|
(11)
|
(8)
|
|
Blujepa
|
2
|
–
|
–
|
2
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Other
General Medicines
|
2,041
|
(9)
|
(7)
|
126
|
(24)
|
(22)
|
479
|
7
|
4
|
1,436
|
(11)
|
(8)
|
|
General Medicines
|
7,024
|
(7)
|
(5)
|
2,762
|
(9)
|
(7)
|
1,491
|
–
|
(2)
|
2,771
|
(7)
|
(4)
|
Commercial Operations turnover
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
£m
|
AER%
|
CER%
|
|
Three
months ended 30 September 2026
|
8,887
|
4
|
5
|
4,931
|
8
|
10
|
1,928
|
3
|
3
|
2,028
|
(4)
|
(3)
|
|
Nine
months ended 30 September 2026
|
24,925
|
4
|
5
|
12,976
|
5
|
7
|
6,053
|
11
|
8
|
5,896
|
(4)
|
(2)
|
Segment information
Operating
segments are reported based on the financial information provided
to the Chief Executive Officer, who is the Chief Operating Decision
Maker, as well as based on the responsibilities of the Executive
Committee ("ExCom"). GSK reports results under two segments:
Commercial Operations and Total R&D. The Group reviews its
assessment of reportable segments on an ongoing basis.
Adjusting
items reconciling segment profit and operating profit comprise
items not specifically allocated to segment profit. Details of
adjusting items can be found on pages 14-19.
Turnover by segment
|
|
|
|
|
|
|
|
|
|
|
|
Q3 2026
£m
|
Q3
2025
£m
|
AER
%
|
CER
%
|
9 months 2026
£m
|
9
months 2025
£m
|
AER
%
|
CER
%
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
8,887
|
8,547
|
4
|
5
|
24,925
|
24,049
|
4
|
5
|
Operating profit by segment
|
|
|
|
|
|
|
|
|
|
|
|
|
Q3 2026
£m
|
Q3
2025
£m
|
AER
%
|
CER
%
|
|
9 months 2026
£m
|
9
months 2025
£m
|
AER
%
|
CER
%
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
4,892
|
4,514
|
8
|
10
|
|
13,559
|
12,540
|
8
|
10
|
|
Research
and Development
|
(1,787)
|
(1,489)
|
20
|
21
|
|
(4,776)
|
(4,309)
|
11
|
12
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
3,105
|
3,025
|
3
|
4
|
|
8,783
|
8,231
|
7
|
9
|
|
Corporate
and other unallocated costs
|
(29)
|
(40)
|
|
|
|
(257)
|
(82)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
3,076
|
2,985
|
3
|
5
|
|
8,526
|
8,149
|
5
|
7
|
|
Adjusting
items
|
(949)
|
(392)
|
|
|
|
(3,625)
|
(1,317)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
2,127
|
2,593
|
(18)
|
(16)
|
|
4,901
|
6,832
|
(28)
|
(25)
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
29
|
26
|
|
|
|
109
|
130
|
|
|
|
Finance
costs
|
(219)
|
(167)
|
|
|
|
(568)
|
(513)
|
|
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(2)
|
4
|
|
|
|
(9)
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
1,935
|
2,456
|
(21)
|
(19)
|
|
4,433
|
6,451
|
(31)
|
(28)
|
Commercial Operations
Core
operating profit growth in Q3 2026 and YTD 2026 primarily reflected
higher turnover, favourable product and regional mix, ongoing
productivity initiatives and supply chain optimisation, higher
royalty income and favourable net legal settlements and expenses in
Q1 2026, partly offset by increased investment in asset
launches.
Total R&D
The
R&D segment operating expense increased in Q3 2026 and YTD 2026
reflecting progression across the portfolio, primarily in Oncology.
This included acceleration in work on ADCs Ris-Rez and Mo-Rez, and
velzatinib and, following the Nuvalent acquisition, on Jideytro (zidesamtinib), approved by
the FDA in the quarter and neladalkib. In Specialty Medicines,
increased investment was driven by efimosfermin acquired in Q3
2025, depemokimab COPD indication and all indications of
felcorekibart (the anti-TSLP monoclonal antibody). Growth was
partly offset by lower spend on bepirovirsen which was filed in Q1
2026. Investment also increased on clinical trial programmes
associated with mRNA seasonal flu vaccines.
Legal matters
The
Group is involved in significant legal and administrative
proceedings, principally product liability, intellectual property,
tax, anti-trust, consumer fraud and governmental investigations,
which are more fully described in the ‘Legal
Proceedings’ note in the Annual Report 2025. At 30 September
2026, the Group’s aggregate provision for legal and other
disputes (not including tax matters described on pages 6 and 7) was
£202 million (31 December 2025: £210
million).
The
Group may become involved in significant legal proceedings in
respect of which it is not possible to meaningfully assess whether
the outcome will result in a probable outflow, or to quantify or
reliably estimate the liability, if any, that could result from
ultimate resolution of the proceedings. In these cases, the Group
would provide appropriate disclosures about such cases, but no
provision would be made.
The
ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The Group’s position could change over time, and, therefore,
there can be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed by a material
amount the amount of the provisions reported in the Group’s
financial accounts.
Significant
legal developments since the date of the Q2 2026
results:
Commercial and corporate
Tesaro, Inc. v. AnaptysBio
A
post-trial hearing was held before the Delaware Chancery Court on
20 October 2026. A decision is expected in Q4 2026 or Q1
2027.
Intellectual Property
Trelegy Ellipta
The
U.S. District Court for the Southern District of Florida has
consolidated the two Trelegy patent infringement cases which
GSK filed against Transpire. Both cases have been set for trial on
22 February 2028.
Returns to shareholders
Quarterly dividends
The
Board has declared a third interim dividend for Q3 2026 of 17p per
share (Q3 2025: 16p per share).
Dividends
remain an essential component of total shareholder return and GSK
recognises the importance of dividends to shareholders. On 23 June
2021, at the GSK Investor Update, GSK set out that from 2022 a
progressive dividend policy will be implemented guided by a 40 to
60 per cent pay-out ratio through the investment cycle. Consistent
with this, GSK has declared a dividend of 17p per share for Q3
2026. The expected dividend for 2026 is 70p per share. In setting
its dividend policy, GSK considers the capital allocation
priorities of the Group and its investment strategy for growth
alongside the sustainability of the dividend.
|
|
|
|
|
|
|
Dividend
dates
|
Ex-dividend date
(Ordinary shares)
|
Ex-dividend date
(ADRs)
|
Record date
|
Payment date
|
|
Q3
2026
|
12
November 2026
|
13
November 2026
|
13
November 2026
|
7
January 2027
|
Ordinary
shareholders may participate in the dividend reinvestment plan
(DRIP). The last date for DRIP elections is 14 December 2026. The
equivalent interim dividend receivable by ADR holders will be
calculated based on the exchange rate on 5 January 2027. An annual
fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by
the Depositary.
|
|
|
|
|
|
|
Paid/
Payable
|
Pence per
share
|
£m
|
|
2026
|
|
|
|
|
First
interim
|
9 July
2026
|
17
|
682
|
|
Second
interim
|
8
October 2026
|
17
|
682
|
|
Third
interim
|
7
January 2027
|
17
|
682
|
|
|
|
|
|
|
2025
|
|
|
|
|
First
interim
|
10 July
2025
|
16
|
650
|
|
Second
interim
|
9
October 2025
|
16
|
646
|
|
Third
interim
|
8
January 2026
|
16
|
643
|
|
Fourth
interim
|
9 April
2026
|
18
|
727
|
|
|
|
66
|
2,666
|
Share capital in issue
At 30
September 2026, 4,009 million shares (Q3 2025: 4,026 million) were
in free issue (excluding Treasury shares and shares held by the
ESOP Trusts). The Company issued a small number of shares in the
quarter (Q3 2025: minimal number) under employee share schemes for
net proceeds of £0.4 million (Q3 2025: £0.4
million).
On 5
February 2025, GSK announced a £2 billion share buyback
programme to be completed over an 18-month period. This share
buyback programme was completed on 26 June 2026, with a total of
124 million shares repurchased and being held as Treasury shares,
at a cost of £2,011 million including transaction costs of
£11 million.
At 30
September 2026, the Company held 271 million Treasury shares at a
cost of £4,580 million, of which 147 million shares at a cost
of £2,571 million were repurchased as part of previous share
buyback programmes, which has been deducted from retained
earnings.
At 30
September 2026, the ESOP Trusts held 36.5 million shares, of which
35.9 million were held for the future exercise of share options and
share awards and 0.6 million were held for the Executive
Supplemental Savings plan. The carrying amount of
£114 million has been deducted from other reserves.
The market value of these shares was £670
million.
Weighted average number of shares
The
numbers of shares used in calculating basic and diluted earnings
per share are reconciled below:
|
|
|
|
|
|
|
|
Q3 2026
millions
|
Q3
2025
millions
|
9 months 2026
millions
|
9
months 2025
millions
|
|
Weighted
average number of shares – basic
|
4,009
|
4,034
|
4,015
|
4,062
|
|
Dilutive
effect of share options and share awards
|
64
|
68
|
64
|
67
|
|
Weighted
average number of shares – diluted
|
4,073
|
4,102
|
4,079
|
4,129
|
Additional information
Accounting policies and basis of preparation
This
unaudited Results Announcement contains condensed financial
information for the three and nine months ended 30 September 2026
and should be read in conjunction with the Annual Report 2025,
which was prepared in accordance with UK-adopted international
accounting standards in conformity with the requirements of the
Companies Act 2006 and the IFRS Accounting Standards as issued by
the International Accounting Standards Board (IASB). This Results
Announcement has been prepared applying consistent accounting
policies to those applied by the Group in the Annual Report 2025,
except for the adoption of the amended IFRS Accounting Standard as
set out below. Other minor amendments to IFRS Accounting Standards
which were effective from 1 January 2026 did not have a material
impact on the Group accounting policies or Group financial
statements.
●Amendments to the Classification and
Measurement of Financial Instruments - Amendments to IFRS 9
and IFRS 7: the amendments to IFRS 9 ‘Financial
Instruments’, clarify the timing of recognition and
derecognition of a financial asset or financial liability, with a
permitted exception relating to a financial liability paid through
an electronic payment system which may be derecognised prior to its
settlement date where specific conditions are met. GSK has adopted
these new requirements for the reporting period beginning on 1
January 2026 and elected to derecognise financial liabilities paid
through an electronic payment system when the required conditions
have been met. The impact on the Group’s financial statements
on transition as at 1 January 2026 is disclosed below and primarily
relates to cheques which were issued but had not yet cleared from
the bank account before the transition date. As permitted under the
transition requirements, the Group has elected not to restate the
comparative information to reflect the application of these
amendments.
|
|
|
|
|
|
|
As at
1 January 2026
£m
|
Adjustment on initial application of amendments to
IFRS 9 and IFRS 7
£m
|
As at
1 January 2026
as adjusted
£m
|
|
Trade
and other payables
|
(15,381)
|
(43)
|
(15,424)
|
|
Bank
overdrafts (within short-term borrowings)
|
(190)
|
29
|
(161)
|
|
Cash
and cash equivalents
|
3,397
|
14
|
3,411
|
The
Group has not identified any changes to its key sources of
accounting judgements or estimations of uncertainty compared with
those disclosed in the Annual Report 2025.
This
Results Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The full Group accounts for 2025 were published
in the Annual Report 2025, which has been delivered to the
Registrar of Companies and on which the report of the independent
auditor was unqualified and did not contain a statement under
section 498 of the Companies Act 2006.
Contingent liabilities
There
were contingent liabilities at 30 September 2026 in respect of
arrangements entered into as part of the ordinary course of the
Group’s business. No material losses are expected to arise
from such contingent liabilities. Provision is made for the outcome
of legal and tax disputes where it is both probable that the Group
will suffer an outflow of funds and it is possible to make a
reliable estimate of that outflow. Descriptions of the significant
legal disputes to which the Group is a party are set out on page
29, and pages 269 to 272 of the 2025 Annual Report.
Net assets
The
book value of net assets increased by £2,406 million from
£15,956 million at 31 December 2025 to £18,362 million at
30 September 2026. This primarily reflected contribution from Total
comprehensive income for the period and the special dividend from
the ViiV Healthcare shareholding restructure, partly offset by
dividends paid to shareholders, shares repurchased under the share
buyback programme and associated transaction costs.
At 30
September 2026, the net surplus on the Group’s pension plans
was £567 million compared with a net surplus of £229
million at 31 December 2025. This movement was primarily driven by
an increase in the UK and US discount rate from 5.5% to 6.6% and
5.1% to 6.2% respectively, which was partially offset by an
increase to the UK inflation rate from 2.7% to 3.1%.
The
estimated present value of the potential redemption amount of the
Pfizer put option related to ViiV Healthcare, recorded in Other
payables in Current liabilities, was £nil (31 December 2025:
£822 million). The put option liability was fully derecognised
at 31 March 2026 as Pfizer has exited its shareholding in ViiV
Healthcare.
Contingent
consideration amounted to £6,629 million at 30 September 2026
(31 December 2025: £6,733 million) as follows:
|
|
|
|
|
|
Group
30 September 2026
£m
|
Group
31
December 2025
£m
|
|
|
|
|
|
Contingent
consideration estimated present value of amounts payable relating
to:
|
|
|
|
Former
Shionogi-ViiV Healthcare joint venture
|
5,301
|
5,433
|
|
Former
Novartis Vaccines business acquisition
|
632
|
651
|
|
BP
Asset IX, Inc. acquisition
|
236
|
231
|
|
Affinivax
acquisition
|
234
|
219
|
|
Others
|
226
|
199
|
|
Contingent
consideration liability at end of the period
|
6,629
|
6,733
|
Of the
contingent consideration payable to Shionogi at 30 September 2026,
£1,243 million (31 December 2025: £1,194 million) is
expected to be paid within one year.
Movements
in contingent consideration are as follows:
|
|
|
|
|
|
|
|
ViiV Healthcare
|
Group
|
||
|
|
9 months 2026
£m
|
9
months 2025
£m
|
9 months 2026
£m
|
9
months 2025
£m
|
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,433
|
6,061
|
6,733
|
7,280
|
|
Additions
|
–
|
–
|
–
|
280
|
|
Remeasurement
through income statement and other movements
|
920
|
161
|
1,087
|
223
|
|
Cash
payments: operating cash flows
|
(1,052)
|
(956)
|
(1,095)
|
(989)
|
|
Cash
payments: investing activities
|
–
|
–
|
(96)
|
(11)
|
|
Contingent
consideration at end of the period
|
5,301
|
5,266
|
6,629
|
6,783
|
Business acquisitions
On 3
March 2026, GSK acquired 100% of the outstanding equity of RAPT
Therapeutics, Inc. ("RAPT") a California-based clinical stage
biopharmaceutical company for US$2.3 billion (£1.7
billion), including transaction fees. Net of cash acquired, GSK's
upfront investment was approximately US$1.9 billion (£1.4
billion). The transaction gives GSK the global rights to the
ozureprubart programme, excluding mainland China, Macau, Taiwan and
Hong Kong.
On 14
April 2026, GSK acquired 100% of 35Pharma, Inc. ("35Pharma") a
Canada-based, private, clinical-stage biopharmaceutical company for
total consideration of US$1.0 billion (£756 million),
comprising US$988 million (£731 million) upfront and US$34
million (£25 million) of deferred consideration. Net of cash
acquired, GSK's net investment was US$945 million (£700
million). The acquisition provides global rights to HS235, a
potential best-in-class activin signalling inhibitor being
developed for the treatment of pulmonary hypertension.
On 15
July 2026, GSK completed the acquisition of 100% of Nuvalent, Inc.
("Nuvalent") a Boston-based clinical-stage biopharmaceutical
company focused on creating precisely targeted oncology therapies.
Under the terms of the agreement, GSK paid Nuvalent shareholders
US$124 per share at closing for an aggregate equity value of
US$10.8 billion (£8.0 billion), including transaction fees.
Net of cash acquired, GSK's upfront investment was approximately
US$9.6 billion (£7.1 billion). The acquisition includes three
products in lung cancer in a single transaction, including
zidesamtinib (NVL-520) and neladalkib (NVL-655) which are two
potential best-in-class, next-generation, highly selective ROS1 and
ALK inhibitors for the treatment of NSCLC.
During
the period to 30 September 2026, no sales arising from RAPT or
35Pharma were included in Group turnover and no revenue is expected
until regulatory approval is received on the acquired assets. GSK
continues to support the ongoing development of the acquired assets
and consequently these assets will be loss making until regulatory
approval on these assets is received. The impact on Group Total
profit after taxation for the period ended 30 September 2026 from
the RAPT and 35Pharma acquisitions was immaterial. Following US FDA
approval of Jideytro
(zidesamtinib) on 22 July 2026, Nuvalent began commercial sales.
Revenue was not material to Group turnover. Nuvalent contributed a
Total operating loss of US$148 million (£110 million) to the
Group Total operating profit for the period since 15 July 2026. The
acquired assets that remain in development will be integrated into
the Group’s existing R&D activities, after which it will
be impracticable to quantify these development costs or the impact
on Group Total profit after taxation.
The
initial acquisition accounting for Nuvalent was reflected in the
third quarter of 2026 on a provisional basis. The accounting for
RAPT and 35Pharma also remains provisional and subject to
change.
Goodwill
of £1.2 billion (£211 million for RAPT, £106 million
for 35Pharma and £852 million for Nuvalent) has been
recognised. The goodwill represents specific synergies available to
GSK from the business combination. The goodwill has been allocated
to the Group’s Commercial Operations and R&D segments.
None of the goodwill is expected to be deductible for tax
purposes.
The
provisional fair values of the net assets acquired, including
goodwill, are as follows:
|
|
|
|
|
|
|
|
RAPT
|
35Pharma
|
Nuvalent
|
Total
|
|
|
£m
|
£m
|
£m
|
£m
|
|
Net
assets acquired:
|
|
|
|
|
|
Intangible
assets
|
1,457
|
700
|
8,077
|
10,234
|
|
Property,
plant & equipment
|
1
|
–
|
–
|
1
|
|
Other
non-current assets
|
–
|
–
|
17
|
17
|
|
Inventory
|
–
|
–
|
24
|
24
|
|
Trade
and other receivables
|
–
|
–
|
10
|
10
|
|
Cash
and cash equivalents
|
281
|
56
|
897
|
1,234
|
|
Other
net liabilities
|
(13)
|
(1)
|
(86)
|
(100)
|
|
Other
long-term liabilities
|
–
|
–
|
(446)
|
(446)
|
|
Deferred
tax liabilities
|
(252)
|
(105)
|
(1,305)
|
(1,662)
|
|
|
1,474
|
650
|
7,188
|
9,312
|
|
Goodwill
|
211
|
106
|
852
|
1,169
|
|
Total
consideration
|
1,685
|
756
|
8,040
|
10,481
|
The
total consideration of £10.5 billion (£1.7 billion for
RAPT, £0.8 billion for 35Pharma and £8.0 billion for
Nuvalent), was fully paid as at 30 September 2026, including the
£20 million of 35Pharma deferred consideration which was
outstanding at Q2 2026.
Net debt information
Reconciliation of cash flow to movements in net debt
|
|
|
|
|
|
9 months 2026
£m
|
9
months 2025
£m
|
|
Total
Net debt at beginning of the period
|
(14,453)
|
(13,095)
|
|
Adjustment
on initial application of amendments to IFRS 9 on 1 January
2026(1)
|
43
|
–
|
|
Total
Net debt at beginning of the period, as adjusted
|
(14,410)
|
(13,095)
|
|
Increase/(decrease)
in cash and bank overdrafts
|
(530)
|
(666)
|
|
Increase/(decrease)
in liquid investments
|
20
|
(11)
|
|
Repayment
of long-term loans
|
1,466
|
1,402
|
|
Issue
of long-term notes
|
(7,779)
|
(1,979)
|
|
Net
decrease/(increase) in short-term loans
|
246
|
(551)
|
|
Increase
in other short-term loans
|
(11)
|
(112)
|
|
Repayment
of other short-term loans
|
106
|
282
|
|
Repayment
of lease liabilities
|
152
|
166
|
|
Disposal
of lease liabilities related to disposal of subsidiary
|
136
|
–
|
|
Net
debt of subsidiary undertakings acquired
|
(2)
|
(1)
|
|
Exchange
adjustments
|
(85)
|
241
|
|
Other
non-cash movements
|
(48)
|
(120)
|
|
Decrease/(increase)
in Net debt
|
(6,329)
|
(1,349)
|
|
Total
Net debt at end of the period
|
(20,739)
|
(14,444)
|
(1) For further
details see page 31
Net debt analysis
|
|
|
|
|
|
30 September 2026
£m
|
31
December 2025
£m
|
|
Liquid
investments
|
28
|
9
|
|
Cash
and cash equivalents
|
2,934
|
3,397
|
|
Short-term
borrowings
|
(2,001)
|
(3,012)
|
|
Long-term
borrowings
|
(21,700)
|
(14,708)
|
|
Liabilities
relating to assets held for sale
|
–
|
(139)
|
|
Total
Net debt at the end of the period
|
(20,739)
|
(14,453)
|
Free cash flow reconciliation
|
|
|
|
|
|
|
|
Q3 2026
£m
|
Q3
2025
£m
|
9 months 2026
£m
|
9
months 2025
£m
|
|
|
|
|
|
|
|
Net
cash inflow/(outflow) from operating activities
|
2,809
|
2,222
|
6,640
|
5,463
|
|
Purchase
of property, plant and equipment
|
(374)
|
(311)
|
(923)
|
(775)
|
|
Proceeds
from sale of property, plant and equipment
|
3
|
5
|
33
|
11
|
|
Purchase
of intangible assets
|
(159)
|
(568)
|
(706)
|
(1,185)
|
|
Proceeds
from disposals of intangible assets
|
1
|
36
|
356
|
112
|
|
Net
finance costs
|
(66)
|
(34)
|
(331)
|
(267)
|
|
Dividends and
distributions from associates and joint ventures
|
54
|
–
|
79
|
–
|
|
Contingent
consideration paid (reported in investing activities)
|
(88)
|
(5)
|
(96)
|
(11)
|
|
Dividend
distributions to non-controlling interests
|
(102)
|
(99)
|
(354)
|
(279)
|
|
Other
distributions to non-controlling interests
|
–
|
–
|
(1,399)
|
–
|
|
Contributions
from non-controlling interests
|
–
|
–
|
1,588
|
–
|
|
Free
cash inflow/(outflow)
|
2,078
|
1,246
|
4,887
|
3,069
|
Related party transactions
There
were no material related party transactions entered into and there
have been no material changes to the related party transactions
disclosed on page 241 of the 2025 Annual Report.
R&D Commentary
Pipeline Overview
|
|
|
|
|
|
Medicines
and vaccines in phase III development (including major lifecycle
innovation or under regulatory review)
|
21
|
Respiratory, Immunology & Inflammation (5)
|
|
|
●
|
Benlysta (anti-B lymphocyte stimulator (BlyS) mAb) systemic
sclerosis-associated interstitial lung disease (SSc-ILD),
connective tissue disease-associated interstitial lung disease
[MR1.1] (CTD-ILD)
|
||
|
●
|
Exdensur (ultra long-acting
anti-IL5 biologic), eosinophilic granulomatosis with polyangiitis
(EGPA), hyper-eosinophilic syndrome (HES), chronic obstructive
pulmonary disease (COPD)
|
||
|
●
|
efimosfermin
(FGF21 analog) metabolic dysfunction-associated steatohepatitis
(MASH)
|
||
|
●
|
felcorekibart
(TSLP) asthma, chronic rhinosinusitis with nasal polyps,
COPD
|
||
|
●
|
Ventolin (salbutamol, Beta 2
adrenergic receptor agonist) asthma
|
||
|
Oncology (8)
|
|||
|
●
|
Blenrep (anti-BCMA ADC) 1L
multiple myeloma
|
||
|
●
|
Jemperli (anti-PD-1) 1L
endometrial cancer, colon cancer, rectal cancer (ph II
registrational), head and neck cancer
|
||
|
●
|
Jideytro (ROS-1 inhibitor)
non-small cell lung cancer
|
||
|
●
|
Zejula (PARP inhibitor)
glioblastoma
|
||
|
●
|
Mo-Rez
(B7-H4 ADC) 2L+ advanced endometrial cancer, platinum resistant
ovarian cancer, platinum sensitive ovarian cancer, and 1L
maintenance ovarian and endometrial cancers
|
||
|
●
|
neladalkib
(ALK inhibitor) non-small cell lung cancer
|
||
|
●
|
Ris-Rez
(B7-H3 ADC) 2L extensive-stage small cell lung cancer, late-line
metastatic castration-resistant prostate cancer
|
||
|
●
|
velzatinib
(KIT inhibitor) gastro-intestinal stromal tumours
|
||
|
HIV (1)
|
|||
|
●
|
New
intramuscular formulation of cabotegravir + rilpivirine (3x a year
treatment)
|
||
|
Infectious Diseases (7)
|
|||
|
●
|
Arexvy (RSV vaccine) RSV, adults 18 years of age and
above
|
||
|
●
|
bepirovirsen
(HBV ASO) chronic hepatitis B
|
||
|
●
|
Bexsero (meningococcal B vaccine) infants (US)
|
||
|
●
|
GSK'116
(varicella vaccine) varicella new seed, individuals 12 months of
age and older
|
||
|
●
|
GSK'371
(MMRV vaccine) MMRV new seed
|
||
|
●
|
Shingrix (recombinant protein, adjuvanted vaccine)
MACE
|
||
|
●
|
mRNA
seasonal flu (double target flu HA-NA vaccine
candidate)
|
||
|
Total
medicines and vaccines in all phases of clinical
development
|
62
|
|
|
|
Total
projects in clinical development (inclusive of all phases and
indications)
|
97
|
|
|
Therapy area updates
The following
provides updates on key medicines and vaccines by therapy area that
will help drive growth for GSK to meet its future
outlooks.
Respiratory,
Immunology & Inflammation
efimosfermin (FGF21
analog)
Efimosfermin
(GSK6519754) is an investigational, once-monthly subcutaneous
injection of a long-acting variant of FGF21, designed to regulate
key metabolic pathways to decrease liver fat, ameliorate liver
inflammation, and reverse liver fibrosis in patients with metabolic
dysfunction-associated steatohepatitis (MASH).
Multiple phase III
trials are ongoing for efimosfermin including both moderate and
advanced fibrosis (F2 to F3) and compensated cirrhosis (F4) caused
by MASH. In August, GSK also started the ALLSTAR phase II trial
investigating efimosfermin for alcohol-related liver disease
(ALD).
Efimosfermin has
received Breakthrough Therapy Designation from the US Food and Drug
Administration (FDA) and Priority Medicines (PRIME) Designation
from the European Medicines Agency (EMA) for the treatment of MASH.
In September, China’s Center for Drug Evaluation (CDE)
granted an additional Breakthrough Therapy Designation for F4 MASH,
building on earlier designations in F2-F3 MASH. Breakthrough
Designation is designed to expedite the development and review of
medicines for serious conditions, where preliminary clinical
evidence indicates potential for substantial improvement over
available therapy. PRIME designation provides scientific and
regulatory support for medicines that have the potential to address
significant unmet medical need.
Key
trials for efimosfermin:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ZENITH-1
(metabolic dysfunction-associated steatohepatitis)
NCT07221227
|
III
|
A phase
III, randomised, double-blind, placebo-controlled, 3-arm study to
investigate the safety and efficacy of efimosfermin alfa in
participants with biopsy-confirmed F2- or F3-stage metabolic
dysfunction-associated steatohepatitis (MASH)
|
Trial
start:
Q4
2025
|
Recruiting
|
|
ZENITH-2
(metabolic dysfunction-associated steatohepatitis)
NCT07221188
|
III
|
A phase
III, randomised, double-blind, placebo-controlled, 3-arm study to
investigate the safety and tolerability of efimosfermin alfa in
participants with known or suspected F2- or F3-stage metabolic
dysfunction-associated steatohepatitis (MASH)
|
Trial
start:
Q4
2025
|
Recruiting
|
|
NEBULA-1
(metabolic dysfunction-associated steatohepatitis)
NCT07701993
|
III
|
A phase
III, double-blind, 2-arm study to investigate the safety and
efficacy of efimosfermin alfa injection compared with placebo in
adult participants with compensated cirrhosis (stage F4 fibrosis)
due to metabolic dysfunction-associated steatohepatitis
(MASH)
|
Trial
start:
Q3
2026
|
Recruiting
|
|
NEBULA-2
(metabolic dysfunction-associated steatohepatitis)
NCT07704892
|
III
|
A phase
III, two-part, double-blind, randomised, placebo-controlled study
to investigate the safety and efficacy of efimosfermin alfa
injection in adult participants with biopsy-confirmed compensated
cirrhosis (stage F4 fibrosis) due to metabolic
dysfunction-associated steatohepatitis (MASH)
|
Trial
start:
Q3
2026
|
Recruiting
|
Exdensur (depemokimab; ultra-long-acting
anti-IL5)
Exdensur (depemokimab) is the first and
only ultra-long-acting biologic to address severe asthma and
chronic rhinosinusitis with nasal polyps (CRSwNP). It is engineered
to have an extended half-life and high binding affinity and potency
for IL-5, enabling twice-yearly dosing.
Exdensur is approved in over 40
countries for the treatment of severe asthma and CRSwNP, including
EU, China, Japan, UK, Canada and Brazil, and for the treatment of
severe asthma in the US.
Depemokimab is
currently being evaluated in phase III trials for the treatment of
other diseases with underlying type 2 inflammation, including OCEAN
for eosinophilic granulomatosis with polyangiitis (EGPA) and
DESTINY for hypereosinophilic syndrome (HES). GSK has also
initiated the ENDURA-1, ENDURA-2 and VIGILANT phase III trials
assessing the efficacy and safety of depemokimab as an add-on
therapy in patients with uncontrolled moderate to severe COPD with
type 2 inflammation.
At
the 2026 European Respiratory Society (ERS) Congress, GSK presented
data reinforcing depemokimab's differentiated profile, including
sustained efficacy over two years in patients with severe asthma
and consistent outcomes across key patient subgroups. Results from
a patient preference study were also presented showing patient
preference for less frequent dosing and identifying dosing
frequency as a key reason for non-adherence.
Key
phase III trials for depemokimab:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
OCEAN
(EGPA)
NCT05263934
|
III
|
A
52-week, randomised, double-blind, double-dummy, parallel-group,
multicentre, non-inferiority study to investigate the efficacy and
safety of depemokimab compared with mepolizumab in adults with
relapsing or refractory eosinophilic granulomatosis with
polyangiitis (EGPA) receiving standard of care therapy
|
Trial
start:
Q3
2022
|
Active,
not recruiting
|
|
DESTINY
(HES)
NCT05334368
|
III
|
A
52-week, randomised, placebo-controlled, double-blind, parallel
group, multicentre trial of depemokimab in adults with uncontrolled
HES receiving standard of care therapy
|
Trial
start:
Q3
2022
|
Active,
not recruiting
|
|
ENDURA-1
(COPD)
NCT06959095
|
III
|
A
randomised, double-blind, placebo-controlled, parallel-group,
multicentre study of the efficacy and safety of depemokimab in
adult participants with COPD with type 2 inflammation
|
Trial
start:
Q2
2025
|
Recruiting
|
|
ENDURA-2
(COPD)
NCT06961214
|
III
|
A
randomised, double-blind, placebo-controlled, parallel-group,
multicentre study of the efficacy and safety of depemokimab in
adult participants with COPD with type 2 inflammation
|
Trial
start:
Q2
2025
|
Recruiting
|
|
VIGILANT
(COPD)
NCT07177339
|
III
|
A
randomised, double-blind, parallel group, placebo-controlled study
of the efficacy and safety of early depemokimab initiation as
add-on treatment in COPD patients with type 2
inflammation
|
Trial
start:
Q4
2025
|
Recruiting
|
felcorekibart (GSK5784283; anti-TSLP)
Felcorekibart
(GSK5784283) is an investigational ultra-long-acting monoclonal
antibody targeting thymic stromal lymphopoietin (TSLP), a key
driver of inflammation across multiple respiratory
diseases.
In
2026, GSK initiated a broad global phase III development programme
for felcorekibart across multiple respiratory diseases. The PERSIST
programme comprises six Phase III trials, with two studies each in
uncontrolled asthma, chronic rhinosinusitis with nasal polyps
(CRSwNP), and chronic obstructive pulmonary disease (COPD). These
studies are evaluating the efficacy and safety of felcorekibart as
an add-on treatment in patients with inadequately controlled
disease.
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
PERSIST
ASTHMA-1
NCT07780643
|
III
|
A
multicentre, randomised, double-blind, placebo-controlled,
parallel-group study to evaluate the efficacy and safety of
felcorekibart (GSK5784283) as an add-on therapy in adults and
adolescents with uncontrolled asthma
|
Trial
start:
Q3
2026
|
Recruiting
|
|
PERSIST
ASTHMA-2
NCT07782996
|
III
|
A
multicentre, randomised, double-blind, placebo-controlled,
parallel-group study to evaluate the efficacy and safety of
felcorekibart (GSK5784283) as an add-on therapy in adults and
adolescents with uncontrolled asthma
|
Trial
start:
Q3
2026
|
Recruiting
|
|
PERSIST
CRSwNP-1
NCT07782970
|
III
|
A
randomised, double-blind, parallel-group Phase III study to assess
the efficacy and safety of felcorekibart (GSK5784283) in
participants with chronic rhinosinusitis with nasal polyps
(CRSwNP)
|
Trial
start:
Q3
2026
|
Recruiting
|
|
PERSIST
CRSwNP-2
NCT07782957
|
III
|
A
randomised, double-blind, parallel-group Phase III study to assess
the efficacy and safety of felcorekibart (GSK5784283) compared with
placebo in participants with chronic rhinosinusitis with nasal
polyps (CRSwNP)
|
Trial
start:
Q3
2026
|
Recruiting
|
|
PERSIST
COPD-1
NCT07780669
|
III
|
A
randomised, double-blind, placebo-controlled, parallel-group,
multicentre study of the efficacy and safety of felcorekibart
(GSK5784283) in participants 40 to 80 years of age with moderate to
very severe COPD
|
Trial
start:
Q3
2026
|
Recruiting
|
|
PERSIST
COPD-2
NCT07780656
|
III
|
A
randomised, double-blind, placebo-controlled, parallel-group,
multicentre study of the efficacy and safety of felcorekibart
(GSK5784283) in participants 40 to 80 years of age with moderate to
very severe COPD
|
Trial
start:
Q3
2026
|
Recruiting
|
Oncology
Blenrep
(belantamab
mafodotin)
GSK is continuing
the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma)
clinical development programme to explore the full potential of
belantamab mafodotin, including in earlier lines of treatment. This
includes DREAMM-10, a phase III clinical trial in newly diagnosed
transplant-ineligible patients, who represent over 70% of patients
starting multiple myeloma therapy.
Key
phase III trials for Blenrep:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
DREAMM-7
(2L+ multiple myeloma; MM)
NCT04246047
|
III
|
A
multicentre, open-label, randomised trial to evaluate the efficacy
and safety of the combination of belantamab mafodotin, bortezomib,
and dexamethasone (B-Vd) compared with the combination of
daratumumab, bortezomib and dexamethasone (D-Vd) in participants
with relapsed/refractory multiple myeloma
|
Trial
start:
Q2
2020
Primary
data reported:
Q4 2023
|
Active,
not recruiting; primary endpoint met
|
|
DREAMM-8
(2L+ MM)
NCT04484623
|
III
|
A
multicentre, open-label, randomised trial to evaluate the efficacy
and safety of belantamab mafodotin in combination with pomalidomide
and dexamethasone (B-Pd) versus pomalidomide plus bortezomib and
dexamethasone (P-Vd) in participants with relapsed/refractory
multiple myeloma
|
Trial
start:
Q4
2020
Primary
data reported:
Q1
2024
|
Active,
not recruiting, primary endpoint met
|
|
DREAMM-10
(1L MM)
NCT06679101
|
III
|
A
multicentre, open-label, randomised trial to evaluate the efficacy
and safety of belantamab mafodotin, lenalidomide and dexamethasone
(B-Rd) versus daratumumab, lenalidomide, and dexamethasone (D-Rd)
in participants with newly diagnosed multiple myeloma who are
ineligible for autologous stem cell transplantation
|
Trial
start:
Q4
2024
|
Recruiting
|
Jemperli (dostarlimab)
On 19
October, the US FDA approved Jemperli as the first and only
immunotherapy for adults with stage II and III microsatellite
instability-high (MSI-H) / mismatch repair deficient (dMMR) locally
advanced rectal cancer. Approval was supported by the phase II
AZUR-1 trial, which met its primary objective and demonstrated a
clinically significant proportion of participants achieved
sustained clinical complete responses at 12 months with data
continuing to mature. The approval provides a new treatment
approach that may help eligible patients avoid chemotherapy,
radiation and surgery. Detailed interim findings from the AZUR-1
trial were presented in a late-breaking oral session at the 2026
ESMO Congress in October.
Jemperli plays an important role in GSK’s
immuno-oncology-based research and development programme. It is the
only approved immuno-oncology-based plus carboplatin-paclitaxel
(CP) treatment regimen to demonstrate a statistically significant
and clinically meaningful overall survival benefit vs. CP alone for
the first-line treatment of adult patients with primary advanced or
recurrent endometrial cancer irrespective of biomarker status.
Ongoing pivotal trials include those in the AZUR programme (colon /
rectal cancers), JADE (head and neck cancer), and DOMENICA
(supported-collaborative study with ARCAGY-GINECO in endometrial
cancer).
Key
trials for Jemperli:
|
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RUBY
(1L stage III or IV endometrial cancer)
NCT03981796
|
III
|
A
randomised, double-blind, multicentre trial of dostarlimab plus
carboplatin-paclitaxel with and without niraparib maintenance
versus placebo plus carboplatin-paclitaxel in patients with
recurrent or primary advanced endometrial cancer
|
Trial
start:
Q3
2019
Part 1
data reported:
Q4
2022
Part 2
data reported:
Q4
2023
|
Active,
not recruiting; primary endpoints met
|
|
GARNET
(advanced solid tumours)
NCT02715284
|
I/II
|
A
multicentre, open-label, first-in-human trial evaluating
dostarlimab in participants with advanced solid tumours who have
limited available treatment options
|
Trial
start:
Q1
2016
Primary
data reported:
Q1
2019
|
Active,
not recruiting
|
|
AZUR-1
(stage II/III rectal cancer)
NCT05723562
|
II
|
A
single-arm, open-label trial with dostarlimab monotherapy in
participants with untreated stage II/III dMMR/MSI-H locally
advanced rectal cancer
|
Trial
start:
Q1
2023
Data
reported:
Q3
2026
|
Active,
not recruiting
|
|
AZUR-2
(untreated perioperative T4N0 or stage III colon
cancer)
NCT05855200
|
III
|
An
open-label, randomised trial of perioperative dostarlimab
monotherapy versus standard of care in participants with untreated
T4N0 or stage III MSI-H/dMMR resectable colon cancer
|
Trial
start:
Q3
2023
|
Active,
not recruiting
|
|
JADE
(locally advanced unresected head and neck cancer)
NCT06256588
|
III
|
A
randomised, double-blind, study to evaluate dostarlimab versus
placebo as sequential therapy after chemoradiation in participants
with locally advanced unresected head and neck squamous cell
carcinoma
|
Trial
start:
Q1
2024
|
Active,
not recruiting
|
|
SAPPHIRE
(endometrial cancer)
NCT07860450
|
I/III
|
An
open-label, multicenter, two-part study: a phase 1b dose selection
followed by a randomised phase 3 to evaluate the pharmacokinetics,
efficacy, and safety of subcutaneous dostarlimab plus
carboplatin-paclitaxel versus intravenous dostarlimab plus
carboplatin-paclitaxel in participants with primary advanced or
recurrent endometrial cancer
|
Trial
start:
Q4
2026
|
Not
active, not recruiting
|
|
DOMENICA*
(relapsed or advanced dMMR endometrial cancer)
NCT05201547
*supported-collaborative
study with ARCAGY-GINECO
|
III
|
A
randomised, multicentre study to evaluate the efficacy and safety
of dostarlimab versus carboplatin-paclitaxel in patients with dMMR
relapsed or advanced endometrial cancer
|
Trial
start:
Q2
2022
|
Active,
not recruiting
|
Risvutatug rezetecan (Ris-Rez)
Ris-Rez is a novel
investigational antibody-drug conjugate targeting the B7-H3
protein, which is highly expressed in more than 10 solid tumour
types, supporting the ambition of GSK’s EMBOLD global trial
programme to develop Ris-Rez across more than 40 indications by
2040.
In
September 2026, GSK started its second global phase III trial for
Ris-Rez, EMBOLD Prostate-302, studying Ris-Rez in patients with
metastatic castration-resistant prostate cancer.
Also in September,
GSK's licensor Hansoh Pharma presented pivotal phase III data at
the World Conference on Lung Cancer showing Ris-Rez significantly
reduced the risk of death versus topotecan in patients with
relapsed small cell lung cancer (SCLC) in China. The results
provide further momentum for GSK’s global development of
Ris-Rez across later-line and earlier treatment settings for
SCLC.
At
the 2026 ESMO Congress in October, GSK presented the first global
data for Ris-Rez in patients with relapsed extensive-stage SCLC.
Results from the phase Ib dose-optimisation portion of the EMBOLD
PanTumour-101 trial showed positive anti-tumour activity and a
manageable safety profile. These results supported selection of the
8 mg/kg dose currently being evaluated in GSK’s global phase
III EMBOLD SCLC-301 trial in the same tumour type.
Also at ESMO,
Hansoh Pharma presented positive data from its second phase III
trial of Ris-Rez this year, ARTEMIS-011 in patients with relapsed
osteosarcoma in China. The results showed Ris-Rez significantly
reduced the risk of disease progression or death compared with
chemotherapy, after a median follow-up of 7.1 months. Safety
findings were consistent with prior findings in this tumour type.
The results will help inform GSK's global development programme,
including an ongoing EMBOLD Sarcoma 202 phase II trial in advanced
osteosarcoma and soft tissue sarcoma.
Key
phase III trials for Ris-Rez:
|
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EMBOLD-SCLC-301
NCT07099898
|
III
|
A
multicenter, randomised, open-label study of risvutatug rezetecan
compared with topotecan in participants with relapsed small cell
lung cancer
|
Trial
start:
Q3
2025
|
Recruiting
|
|
EMBOLD
Prostate-302 (prostate cancer)
NCT07802704
|
III
|
A
multicenter, randomised, open-label study of risvutatug rezetecan
compared with best supportive standard of care, with or without
androgen receptor pathway inhibitors, in participants with
metastatic castration-resistant prostate cancer
|
Trial
start:
Q3
2026
|
Recruiting
|
Mocertatug rezetecan (Mo-Rez)
GSK is
advancing Mo-Rez, a B7-H4–targeting investigational
antibody-drug conjugate, through the global BEHOLD development
programme across multiple gynaecological cancer indications, where
significant unmet need remains. B7-H4 is an immune checkpoint that
is widely expressed in ovarian and endometrial cancers, and is low
in normal tissues, making it a promising target for clinical
development.
Five phase III
pivotal trials for Mo-Rez have been initiated and are actively
recruiting patients: BEHOLD-Ovarian01 in platinum-resistant ovarian
cancer (PROC), BEHOLD-Endometrial01 in advanced or recurrent
endometrial cancer, BEHOLD-Ovarian02 in platinum sensitive ovarian
cancer, BEHOLD-Ovarian03 in first-line maintenance ovarian cancer
without homologous recombination deficiency and
BEHOLD-Endometrial02 in first line maintenance mismatch
repair–proficient endometrial cancer.
In
October 2026, GSK presented the latest safety positive data for
Mo-Rez from the global phase I BEHOLD-1 trial at ESMO demonstrating
clinically meaningful and durable responses at >13 months follow
up, alongside a manageable safety for patients with PROC. The
response to Mo-Rez observed across a range of B7-H4 expression
levels reinforces its broad potential in gynaecologic cancers and
further validates the relevance of targeting B7-H4.
Key
phase III trials for Mo-Rez:
|
|
|
|
|
|
|||||
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|||||
|
BEHOLD-Ovarian01
GOG-3132
/ ENGOT-o98 / APGOT-OV21
NCT07286266
|
III
|
A
randomised, Open-label, Multicenter, Phase III Study to Investigate
mocertatug rezetecan Compared With Chemotherapy in Participants
With Platinum-resistant Ovarian Cancer
|
Trial
start:
Q2
2026
|
Recruiting
|
|||||
|
BEHOLD-Endometrial01
GOG-3131
/ ENGOT-en34 / APGOT-EN4
NCT07286331
|
III
|
A
randomised, Open-label, Multicenter, Phase III Study to Investigate
mocertatug rezetecan Compared With Chemotherapy in Participants
With Recurrent Endometrial Cancer
|
Trial
start:
Q2
2026
|
Recruiting
|
|||||
|
BEHOLD-Ovarian02
/ GOG-3136 / ENGOT-ov99 / APGOT-OV19
NCT07684612
|
III
|
A
randomised, Open-Label, Multicenter, Phase 3 Study to Investigate
Mocertatug Rezetecan With Bevacizumab Compared With Platinum
Doublet With Bevacizumab in Participants With Platinum-Sensitive
Ovarian Cancer
|
Trial
start:
Q3
2026
|
Recruiting
|
|||||
|
|
|||||||||
|
|
|
|
|
|
Trial name
(population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
|
|
|
|
|
BEHOLD-Ovarian03 /
GOG-3135 / ENGOT-ov105 / APGOT-OV20
NCT07694427
|
III
|
A
randomised, Open-label, Multicenter, Phase 3 Study to Investigate
Mocertatug Rezetecan With or Without Bevacizumab in Comparison to
Active Observation With or Without Bevacizumab as Maintenance
Treatment in Participants With Newly Diagnosed FIGO Stage III/IV
Non-Homologous Recombination Deficient Ovarian Cancer
|
Trial
start:
Q4
2026
|
Recruiting
|
|
|
|
|
|
|
BEHOLD-Endometrial02
/ ENGOT-en33 / GOG-3130 / APGOT-EN5
NCT07684599
|
III
|
A
randomised, Open-label, Multicenter, Phase 3 Study to Investigate
Mocertatug Rezetecan in Combination With Immune Checkpoint
Inhibition for Maintenance Treatment of Participants With Mismatch
Repair Proficient (MMRp) Endometrial Cancer
|
Trial
start:
Q3
2026
|
Recruiting
|
Jideytro
(zidesamtinib)
Jideytro (zidesamtinib) is a ROS1 tyrosine kinase inhibitor
(TKI) approved by the US FDA for the treatment of adult patients
with locally advanced or metastatic ROS1-positive non-small cell
lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor. The
FDA approval is based on results from the ARROS-1 (NCT05118789)
global phase I/II trial evaluating zidesamtinib in patients with
advanced ROS1 positive NSCLC and other ROS1-positive solid
tumours.
Jideytro is GSK's first approved medicine in lung cancer and
was added to the portfolio through the acquisition of
Nuvalent.
In September 2026, GSK announced positive results
from the registrational phase I/II ARROS-1 trial evaluating
zidesamtinib in patients with advanced or metastatic ROS1-positive
TKI-naïve NSCLC. The data were presented in a Presidential
Symposium session at the 2026 World Conference on Lung Cancer and
will support a planned supplemental New Drug Application to the US
FDA this year to expand the indication to include first-line
treatment.
Key trials for Jideytro:
|
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ARROS-1
(ROS1+ non-small cell lung cancer and other solid tumours;
NSCLC)
|
I/II
|
A study
of the highly selective ROS1 inhibitor zidesamtinib (NVL-520) in
patients with advanced NSCLC and other solid tumors
|
Trial
start:
Q1
2022
|
Active
|
neladalkib:
Neladalkib
is an investigational ALK tyrosine kinase inhibitor (TKI) designed
to maintain activity against a broad range of ALK resistance
mutations, while minimising off-target activity and optimising
penetration into the central nervous system
(CNS).
Neladalkib
was previously granted US Breakthrough Therapy designation for the
treatment of patients with locally advanced or metastatic
ALK-positive NSCLC who have been previously treated with 2 or more
ALK TKIs and Orphan Drug designation for ALK-positive
NSCLC.
The
phase I/II ALKOVE-1 study is ongoing in patients with advanced
ALK-positive NSCLC and other solid tumours, and the phase III
ALKAZAR trial is evaluating neladalkib versus alectinib in
first-line ALK-positive NSCLC.
Key
trials for neladalkib:
|
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ALKOVE-1
(ALK+ non-small cell lung cancer and other solid tumours;
NSCLC)
|
I/II
|
A study
of neladalkib (NVL-655) in patients with advanced NSCLC and other
solid tumors harboring ALK rearrangement or activating ALK
mutation
|
Trial
start:
Q2
2022
|
Active
|
|
ALKAZAR
(1L ALK+ non-small cell lung cancer; NSCLC)
|
III
|
A phase
III study of the selective anaplastic lymphoma kinase (ALK)
inhibitor NVL-655 compared to alectinib in first-line treatment of
patients with ALK-positive advanced non-small cell lung cancer
(NSCLC)
|
Trial
start:
Q3
2025
|
Active
|
HIV
As a
pioneer in long-acting injectables, ViiV Healthcare, majority owned
by GSK, remains focused on advancing the next-generation of
INSTI-powered HIV innovation.
In Q3,
topline phase IIIb CROWN data demonstrated Cabenuva’s (cabotegravir +
rilpivirine; CAB + RPV LA) superior efficacy versus standard of
care oral anti-retroviral therapy in people with unsuppressed HIV.
These data address an important unmet need and significant growth
opportunity and will be shared with health authorities for
regulatory review.
At
IDWeek 2026, data were shared adding to the significant body of
clinical and real-world evidence for long-acting injectables.
Five-year OPERA data further reinforced durable effectiveness of
CAB LA + RPV in the real world, while prevention data showed very
low HIV acquisition with CAB LA for PrEP, consistent with
registrational trials. In-vitro data for VH184 – the first
potential third-generation INSTI – were also shared further
highlighting an enhanced resistance profile against first- and
second-generation INSTI-resistant strains.
For the
3x a year long-acting injectable candidate for HIV PrEP (new
intramuscular formulation of cabotegravir), data are now in house
from the EXTEND 4M pharmacokinetic (PK) study. Analyses are
underway to fully characterise the new formulation ahead of sharing
the data package with regulators.
Key HIV
trials:
|
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EXTEND
4M (HIV)
NCT06741397
|
IIb
|
Phase
IIb single arm, repeat dose study to evaluate the PK profile,
safety and tolerability of a new formulation of cabotegravir LA
injected intramuscularly every four months in adolescent and adult
participants at risk of HIV acquisition.
|
Trial
start:
Q4
2024
|
Active,
not recruiting, data analysis underway
|
|
CUATRO
(HIV)
NCT07650916
|
III
|
Phase
III, randomised, multicenter, parallel-group, non-inferiority,
open-label study evaluating the efficacy, safety, and tolerability
of new cabotegravir and rilpivirine formulations or cabotegravir
long-acting plus rilpivirine in adults and adolescents with HIV who
are virologically suppressed on ART
|
Trial
start:
Q2
2026
|
Active,
recruiting
|
Infectious Diseases
Arexvy
(respiratory
syncytial virus vaccine, adjuvanted)
GSK
continues to progress the life-cycle innovation of Arexvy, its Respiratory Syncytial Virus
(RSV) vaccine for adults, with expanded indications in new
populations and geographies.
The
vaccine is approved for the prevention of lower respiratory tract
disease (LRTD) caused by RSV in adults aged 60 years of age and
older in over 70 countries. It is also approved for use in adults
aged 50–59 at increased risk (AIR) for LRTD caused by RSV due
to certain underlying medical conditions in over 60 countries,
including the US and Japan. In the US and Japan, it is approved for
use in adults aged 18–49 years AIR and in the European
Economic Area for adults aged 18 years and older. Arexvy is not for use in pregnant
individuals.
In
July, the US FDA approved an update to the Arexvy prescribing information to
include data in immunocompromised (IC) adults aged 18 years and
older. Arexvy is approved
for use in IC adults aged 18 years and older in the European
Economic Area and in IC adults aged 18 years and older in
Japan.
China’s
Center for Drug Evaluation (CDE) is reviewing a regulatory
application for Arexvy for
the prevention of LRTD caused by RSV in adults aged 60 years and
older. A decision is expected in 2027.
Key trials for Arexvy:
|
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RSV
OA=ADJ-004
(Adults
aged ≥60 years)
NCT04732871
|
III
|
A
randomised, open-label, multi-country trial to evaluate the
immunogenicity, safety, reactogenicity and persistence of a single
dose of the RSVPreF3 OA investigational vaccine and different
revaccination schedules in adults aged 60 years and
above
|
Trial
start:
Q1
2021
Primary
data reported:
Q2
2022
|
Active,
not recruiting; primary endpoint met
|
|
RSV
OA=ADJ-012
(Adults
aged ≥60 years )
NCT06534892
|
IIIb
|
An
extension and crossover vaccination study on the immune response
and safety of a vaccine against Respiratory Syncytial Virus given
to adults 60 years of age and above who participated in RSV
OA=ADJ-006 study
|
Trial
start:
Q3
2024
|
Active,
not recruiting
|
|
RSV
OA=ADJ-031
(Immunocompromised
adults aged ≥18 years)
NCT07092865
|
IIb
|
A
non-randomised, controlled, open-label, extension study to evaluate
the persistence of immune response of the adjuvanted RSVPreF3
vaccine and the safety and immunogenicity following revaccination
in lung and kidney transplant recipients (aged 18 years and
above)
|
Trial
start:
Q3
2025
|
Active,
not recruiting
|
|
RSV
OA=ADJ-028
(Adults
18 to 59 years of age at increased risk for RSV
disease)
NCT07220109
|
III
|
A
randomised, controlled, observer blind, immuno-bridging study to
evaluate immunogenicity, reactogenicity and safety of a single dose
of the RSVPreF3 OA investigational vaccine in Chinese adults 18-59
years of age at increased risk of RSV Disease
|
Trial
start:
Q4
2025
|
Active,
not recruiting
|
mRNA seasonal flu (double target flu HA-NA vaccine
candidate)
In
August 2026, GSK presented positive phase II data for its mRNA
seasonal influenza (flu) vaccine candidate at the OPTIONS XIII
Conference for the Control of Influenza. GSK’s vaccine
candidate showed higher immune responses against all influenza
strains tested compared to licensed standard dose and high dose
inactivated flu vaccines in younger and older adults respectively,
and was generally well tolerated. Based on these results, in
September 2026, GSK started the first phase III trial of an mRNA
flu vaccine designed to target both haemagglutinin (HA) and
neuraminidase (NA), the primary surface antigens that cause the flu
virus to bind and spread. While licensed flu vaccines primarily
target HA, GSK’s vaccine candidate is specifically designed
to also target NA. Growing evidence suggests this could help
improve protection, illness severity and transmission. In July
2026, the US Food and Drug Administration (FDA) granted the vaccine
candidate Fast Track designation for the targeted age indication,
reflecting the urgent need to improve flu protection.
Key
trials:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
DUET-006
(Adults
≥65 Years of Age)
|
III
|
A Phase
3 randomised, Observer-Blind, Controlled Study to Evaluate the
Clinical Efficacy of an mRNA Based Seasonal Influenza Vaccine in
Older Adults ≥65 Years of Age
|
Trial
start: September 2026
|
Recruiting
|
|
DUET-004
(Adults
18-64 Years of Age)
|
III
|
A Phase
3 randomised, Observer-Blind, Controlled Study to Evaluate the
Immunogenicity, Reactogenicity and Safety of an mRNA-based Seasonal
Influenza Vaccine, in adults 18-64 Years of age
|
Trial
start: October 2026
|
Recruiting
|
Hibsago (HBV ASO)
(bepirovirsen)
Hibsago is a triple-action antisense
oligonucleotide - a first in class new treatment option for people
with chronic hepatitis B (CHB). It is designed to inhibit the
replication of viral DNA in the body, suppress the level of
hepatitis B surface antigen (HBsAg) in the blood, and stimulate the
immune system to increase the chances of a durable and sustained
response.
In
August 2026, Hibsago was
approved as a functional cure for CHB in Japan – the first
approval anywhere in the world. This was followed by approval by
the US FDA in October 2026. These decisions were accelerated by
regulatory designations reflecting Hibsago’s innovation and
potential to address significant unmet need in CHB. Reviews are
also underway in other markets including China, supported by
Breakthrough Therapy Designation and Priority Review and the EU.
Further submissions are planned for 2027.
To
further expand development of novel sequential regimens, GSK
entered an agreement for an exclusive worldwide license to develop
and commercialise daplusiran/tomligisiran (GSK5637608, formerly
JNJ-3989), an investigational hepatitis B virus-targeted small
interfering ribonucleic acid (siRNA) therapeutic. This agreement
provides an opportunity to investigate a novel sequential regimen
to pursue functional cure in an even broader patient population
with bepirovirsen. Phase IIb trials for this sequential therapy
started in Q4 2024.
Key
trials for bepirovirsen:
|
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
B-Well
1 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630807
|
III
|
A
multicentre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
|
Completed;
primary endpoint met
|
|
B-Well
2 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630820
|
III
|
A
multicentre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
|
Completed;
primary endpoint met
|
|
B-United
bepirovirsen sequential therapy with daplusiran/tomligisiran in
nucleos(t)ide treated patients (chronic hepatitis B)
NCT06537414
|
IIb
|
A
multicentre, randomised, partially placebo-controlled, double-blind
study to investigate the safety and efficacy of sequential therapy
with daplusiran/tomligisiran followed by bepirovirsen in
participants with chronic hepatitis B virus on background
nucleos(t)ide analogue therapy
|
Trial
start:
Q4
2024
|
Active,
not recruiting
|
|
B-Sure
Long-term Follow-up Study to Evaluate Durability of Treatment
Response in Previous Bepirovirsen Study Participants
NCT04954859
|
II
|
A
global multicenter, long-term follow-up study to assess durability
of efficacy, as measured by maintenance of treatment response from
the parent study, in participants who participated in a previous
bepirovirsen study and achieved a complete or partial response.
Eligible participants will be enrolled in this study after
completing the end of study (EoS) visit in one of five parent
bepirovirsen studies.
|
Trial
Start: Q1 2021
|
Active,
not recruiting
|
Reporting definitions
CAGR (Compound annual growth rate)
CAGR is
defined as the compound annual growth rate and shows the annualised
average rate for growth in sales and core operating profit between
2021 to 2026, assuming growth takes place at an exponentially
compounded rate during those years.
CER and AER growth
In
order to provide investors with a measure of year-on-year growth
excluding the impact of exchange rate movements, it is the
Group’s practice to discuss its results in terms of constant
exchange rate (CER) growth. This represents growth calculated as if
the exchange rates used to determine the results of overseas
companies in Sterling had remained unchanged from those used in the
comparative period. CER% represents growth at constant exchange
rates. For those countries which qualify as hyperinflationary as
defined by the criteria set out in IAS 29 ‘Financial
Reporting in Hyperinflationary Economies’ (Argentina and
Turkey) CER growth is adjusted using a more appropriate exchange
rate where the impact is significant, reflecting depreciation of
their respective currencies in order to provide comparability and
not to distort CER growth rates.
AER%
represents growth at actual exchange rates.
Core Earnings per share
Unless otherwise
stated, Core earnings per share refers to Core basic earnings per
share.
Core
Operating Margin
Core Operating
margin is Core operating profit divided by turnover. Core operating
profit is a key financial measure used by management to evaluate
performance.
Free cash flow
Free
cash flow is defined as the net cash inflow/outflow from operating
activities less capital expenditure on property, plant and
equipment and intangible assets, contingent consideration payments,
net finance costs, and distributions to non-controlling interests,
contributions from non-controlling interests plus proceeds from the
sale of property, plant and equipment and intangible assets, and
dividends received from joint ventures and associates. Free cash
flow provides investors with a measure of cash flows that are
available to pay shareholder distributions and to fund strategic
acquisitions. It is used by management for planning and reporting
purposes and in discussions with and presentations to investment
analysts and rating agencies. Free cash flow growth is calculated
on a reported basis. A reconciliation of net cash inflow from
operations to free cash flow from operations is set out on page
34.
Free cash flow conversion
Free cash flow
conversion is free cash flow from operations as a percentage of
profit attributable to shareholders. Free cash flow conversion
provides investors with a measure of turning profit into
cash.
General Medicines
General
Medicines are usually prescribed in the primary care or community
settings by general healthcare practitioners. For GSK, this
includes medicines for inhaled respiratory, dermatology,
antibiotics and other diseases.
Non-controlling interest (NCI)
Non-controlling
interest is the equity in a subsidiary not attributable, directly
or indirectly, to a parent.
Percentage points
Percentage points
of growth which is abbreviated to ppts.
RAR (Returns and Rebates)
GSK sells to
customers both commercial and government mandated contracts with
reimbursement arrangements that include rebates, chargebacks and a
right of return for certain pharmaceutical products principally in
the US. Revenue recognition reflects gross-to-net sales adjustments
as a result. These adjustments are known as the RAR accruals and
are a source of significant estimation uncertainty and fluctuation
which can have a material impact on reported revenue from one
accounting period to the next.
Risk adjusted sales
Pipeline
risk-adjusted sales are based on the latest internal estimate of
the probability of technical and regulatory success for each asset
in development.
Specialty
Medicines
Specialty Medicines
are typically prescription medicines used to treat complex or rare
chronic conditions. For GSK, this comprises medicines for
infectious diseases, HIV, Respiratory, Immunology &
Inflammation, and Oncology.
Total Net debt
Net debt is defined
as total borrowings less cash, cash equivalents, liquid
investments, and short-term loans to third parties that are subject
to an insignificant risk of change in value. The measure is used by
management as it is considered a good indicator of GSK's ability to
meet its financial commitments and the strength of its balance
sheet (including those classified as assets held for sale and
liabilities relating to assets held for sale).
Total and Core results
Total reported
results represent the Group’s overall performance. GSK uses a
number of non-IFRS measures to report the performance of its
business. Core results and other non-IFRS measures may be
considered in addition to, but not as a substitute for or superior
to, information presented in accordance with IFRS. Core results are
defined on page 14 and other non-IFRS measures are defined in pages
43 and 44.
Total Operating Margin
Total Operating
margin is Total operating profit divided by turnover.
Total Earnings per share
Unless otherwise
stated, Total earnings per share refers to Total basic earnings per
share.
Working capital
Working capital
represents inventory and trade receivables less trade
payables.
Year to date
Year to date is the
nine-month period in the year to 30 September 2026 or the same
prior period in 2025 as appropriate.
Guidance and Outlooks, assumptions and cautionary
statements
2026 Guidance
GSK reaffirms its
full-year 2026 guidance at constant exchange rates
(CER).
GSK expects its
turnover to increase between 3% to 5%, at the upper half of the
range, and Core operating profit to increase between 7% to 9%, at
the upper half of the range. Core earnings per share is expected to
increase between 7% to 9%, at the lower half of the
range.
The Group has made
planning assumptions that we expect turnover for Specialty
Medicines to increase by a low double-digit percentage, Vaccines to
be broadly stable to an increase at a low-single digit percentage,
and General Medicines to decline by a mid-single digit to low
single-digit percentage.
2021-2026 and 2031 Outlooks
In
February 2025, GSK set out improved outlooks for 2031 which are
detailed in the 2024 full year and fourth quarter results on
gsk.com(1).
Assumptions and basis of preparation related to 2026 Guidance,
2021-26 and 2031 Outlooks
In
outlining the guidance for 2026, and outlooks for the period
2021-26 and for 2031, the Group has made certain assumptions about
the macro-economic environment, the healthcare sector (including
regarding existing and possible additional governmental legislative
and regulatory reform), the different markets and competitive
landscape in which the Group operates and the delivery of revenues
and financial benefits from its current portfolio, its development
pipeline and restructuring programmes, including the Accelerate
Growth programme as outlined on page 17.
As
previously announced, on 19 December 2025, GSK entered into an
agreement with the US Administration to lower the cost of
prescription medicines for American patients and exclude both GSK
and ViiV Healthcare from Section 232 tariffs for three years. On 9
April 2026, GSK, ViiV Healthcare, and the US Government entered
into a definitive agreement reflecting Section 232 tariff relief
through 20 January 2029 (subject to implementation and ongoing
compliance). As part of that implementation, GSK and ViiV
Healthcare each signed a GENEROUS Model Manufacturer Participation
Agreement with the Centers for Medicare and Medicaid Services
effective 15 June 2026. With these agreements GSK and ViiV
Healthcare have committed certain products to participate in the
voluntary GENEROUS Model. GSK and ViiV have also entered into
GENEROUS Model Supplemental Rebate Agreements with several
interested states and will work with the other states going forward
to execute Supplemental Rebate Agreements as requested. Our full
year guidance is inclusive of the expected impact of these
agreements.
2026 Guidance
These
planning assumptions as well as operating profit, earnings per
share guidance and dividend expectations assume no material
interruptions to supply of the Group’s products, no material
mergers, acquisitions or disposals, no material litigation or
investigation costs for the Company (save for those that are
already recognised or for which provisions have been made) and no
change in the Group’s shareholdings in ViiV Healthcare. The
assumptions also assume no material changes in the healthcare
environment or unexpected significant changes in pricing or trade
policies, including tariffs (except as noted above), as a result of
government or competitor action. The 2026 guidance factors in all
divestments and product exits announced to date.
2021-26 and 2031 Outlooks
The
assumptions for GSK’s revenue, Core operating profit, Core
operating margin and cash flow outlooks, 2031 revenue outlook and
margin expectations through dolutegravir loss of exclusivity assume
the delivery of revenues and financial benefits from its current
and development pipeline portfolio of medicines and vaccines (which
have been assessed for this purpose on a risk-adjusted basis, as
described further below); regulatory approvals of the pipeline
portfolio of medicines and vaccines that underlie these
expectations (which have also been assessed for this purpose on a
risk-adjusted basis, as described further below); no material
interruptions to supply of the Group’s products; successful
delivery of the ongoing and planned integration and restructuring
plans, including the Accelerate Growth programme as outlined on
page 17; no material mergers, acquisitions or disposals or other
material business development transactions; no material litigation
or investigation costs for the Company (save for those that are
already recognised or for which provisions have been made); and no
change in the Group's shareholdings in ViiV Healthcare. GSK assumes
no premature loss of exclusivity for key products over the
period.
The
assumptions for GSK’s revenue, Core operating profit, Core
operating margin and cash flow outlooks, 2031 revenue outlook and
margin expectations through dolutegravir loss of exclusivity also
factor in all divestments and product exits announced to date as
well as material costs for investment in new product launches and
R&D. Risk-adjusted sales includes sales for potential planned
launches which are risk-adjusted based on the latest internal
estimate of the probability of technical and regulatory success for
each asset in development.
Notwithstanding
our guidance, outlooks and expectations, there is still uncertainty
as to whether our assumptions, guidance, outlooks and expectations
will be achieved.
All
outlook statements are given on a constant currency basis and use
2025 average exchange rates as a base (£1/$1.31,
£1/€1.17, £1/Yen 198).
(1) https://www.gsk.com/media/slrhnzie/fy-2024-results-announcement.pdf
Assumptions and cautionary statement regarding forward-looking
statements
The
Group’s management believes that the assumptions outlined
above are reasonable, and that the guidance, outlooks, and
expectations described in this report are achievable based on those
assumptions. However, given the forward-looking nature of these
guidance, outlooks, and expectations, they are subject to greater
uncertainty, including potential material impacts if the above
assumptions are not realised, and other material impacts related to
foreign exchange fluctuations, macro-economic activity, the impact
of outbreaks, epidemics or pandemics, changes in legislation,
regulation, government actions and policies, including the impact
of any potential tariffs or other restrictive trade policies on the
Group's products, or intellectual property protection, product
development and approvals, actions by our competitors, and other
risks inherent to the industries in which we operate.
This
document contains statements that are, or may be deemed to be,
“forward-looking statements”. Forward-looking
statements give the Group’s current expectations or forecasts
of future events. An investor can identify these statements by the
fact that they do not relate strictly to historical or current
facts. They use words such as 'aim', 'ambition', 'anticipate',
'believe', 'could', 'estimate', 'expect', 'goal', 'intend', 'may',
'outlook', 'plan', 'project', 'seek', 'should', 'target', 'will'
and other words and terms of similar meaning in connection with any
discussion of future operating or financial performance. In
particular, these include statements relating to future actions,
prospective products or product approvals, future performance or
results of current and anticipated products, sales efforts,
expenses, the outcome of contingencies such as legal proceedings,
dividend payments and financial results. Other than in accordance
with its legal or regulatory obligations (including under the
Market Abuse Regulation, the UK Listing Rules and the Disclosure
Guidance and Transparency Rules of the Financial Conduct
Authority), the Group undertakes no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise. The reader should, however, consult any
additional disclosures that the Group may make in any documents
which it publishes and/or files with the SEC. All readers, wherever
located, should take note of these disclosures. Accordingly, no
assurance can be given that any particular expectation will be met
and readers are cautioned not to place undue reliance on the
forward-looking statements.
All
guidance, outlooks and expectations should be read together with
the guidance and outlooks, assumptions and cautionary statements in
this Q3 2026 earnings release and in the Group's 2025 Annual Report
on Form 20-F.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group’s control or precise estimate. The Group cautions
investors that a number of important factors, including those in
this document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under
‘Risk Factors’ in the Group’s Annual Report on
Form 20-F for 2025 and as described on pages 48 and 49 of the Q2
2026 earnings release. Any forward-looking statements made by or on
behalf of the Group speak only as of the date they are made and are
based upon the knowledge and information available to the Directors
on the date of this report.
Independent review report to GSK plc
Conclusion
We
have been engaged by GSK plc (“the company”) to review
the condensed financial information in the Results Announcement of
the company for the three and nine months ended 30 September
2026.
The
condensed financial information comprises:
|
●
|
the
income statement and statement of comprehensive income for the
three and nine month periods ended 30 September 2026 on page 20 and
21;
|
|
●
|
the
balance sheet as at 30 September 2026 on page 22;
|
|
●
|
the
statement of changes in equity for the nine-month period then ended
on page 23;
|
|
●
|
the
cash flow statement for the nine-month period then ended on page
24; and
|
|
●
|
the
accounting policies and basis of preparation and the explanatory
notes to the condensed financial information on pages 25 to 34 that
have been prepared applying consistent accounting policies to those
applied by GSK plc and its subsidiaries (“the Group”)
in the Annual Report 2025, which was prepared in accordance with
UK-adopted international accounting standards in conformity with
the requirements of the Companies Act 2006 and the IFRS Accounting
Standards as issued by the International Accounting Standards Board
(IASB).
|
Based
on our review, nothing has come to our attention that causes us to
believe that the condensed financial information in the Results
Announcement for the three and nine months ended 30 September 2026
is not prepared, in all material respects, in accordance with the
accounting policies set out in the accounting policies and basis of
preparation section on page 31.
Basis for Conclusion
We
conducted our review in accordance with International Standard on
Review Engagements (UK) 2410 “Review of Interim Financial
Information Performed by the Independent Auditor of the
Entity” issued by the Financial Reporting Council for use in
the United Kingdom (ISRE (UK) 2410). A review of interim financial
information consists of making inquiries, primarily of persons
responsible for financial and accounting matters, and applying
analytical and other review procedures. A review is substantially
less in scope than an audit conducted in accordance with
International Standards on Auditing (UK) and consequently does not
enable us to obtain assurance that we would become aware of all
significant matters that might be identified in an audit.
Accordingly, we do not express an audit opinion.
As
disclosed on page 31, the annual financial statements of the Group
are prepared in accordance with United Kingdom adopted
international accounting standards. The condensed set of financial
information included in this Results Announcement have been
prepared in accordance with the accounting policies set out in the
accounting policies and basis of preparation section on page
31.
Conclusion Relating to Going Concern
Based
on our review procedures, which are less extensive than those
performed in an audit as described in the Basis for Conclusion
section of this report, nothing has come to our attention to
suggest that the directors have inappropriately adopted the going
concern basis of accounting or that the directors have identified
material uncertainties relating to going concern that are not
appropriately disclosed.
This
Conclusion is based on the review procedures performed in
accordance with ISRE (UK) 2410; however future events or conditions
may cause the entity to cease to continue as a going
concern.
Responsibilities of the directors
The directors are
responsible for preparing the Results Announcement of the company
in accordance with the Disclosure Guidance and Transparency Rules
of the United Kingdom’s Financial Conduct
Authority.
In
preparing the Results Announcement, the directors are responsible
for assessing the company’s ability to continue as a going
concern, disclosing as applicable, matters related to going concern
and using the going concern basis of accounting unless the
directors either intend to liquidate the company or to cease
operations, or have no realistic alternative but to do
so.
Auditor’s Responsibilities for the review of the financial
information
In
reviewing the Results Announcement, we are responsible for
expressing to the company a conclusion on the condensed financial
information in the Results Announcement. Our Conclusion, including
our Conclusion Relating to Going Concern, are based on procedures
that are less extensive than audit procedures, as described in the
Basis for Conclusion paragraph of this report.
Use of our report
This
report is made solely to the company in accordance with ISRE (UK)
2410. Our work has been undertaken so that we might state to the
company those matters we are required to state to it in an
independent review report and for no other purpose. To the fullest
extent permitted by law, we do not accept or assume responsibility
to anyone other than the company, for our review work, for this
report, or for the conclusions we have formed.
Deloitte LLP
Statutory
Auditor
London, United
Kingdom
28
October 2026
Glossary
|
|
|
|
Terms used in the Announcement
|
Brief description
|
|
1L
|
First
line
|
|
2L
|
Second
line
|
|
ADC
|
Antibody-drug
conjugate
|
|
ADP
|
Adenosine
diphosphate
|
|
ALK
|
Anaplastic
lymphoma kinase
|
|
ASO
|
Antisense
oligonucleotide
|
|
CCL
|
Contingent
consideration liability
|
|
CDC
|
Centers
for Disease Control and Prevention
|
|
CDE
|
Center
for Drug Evaluation
|
|
COPD
|
Chronic
obstructive pulmonary disease
|
|
CRSwNP
|
Chronic
rhinosinusitis with nasal polyps
|
|
cUTI
|
Complicated
urinary tract infection
|
|
dMMR
|
Deficient
mismatch repair
|
|
DRIP
|
Dividend
reinvestment plan
|
|
DTG
|
Dolutegravir
|
|
EGPA
|
Eosinophilic
granulomatosis with polyangiitis
|
|
EMA
|
European
Medicines Agency
|
|
ESOP
|
Employee
share ownership plan
|
|
GENEROUS
|
GENErating
cost Reductions fOr U.S. Medicaid
|
|
GIST
|
Gastrointestinal
stromal tumour
|
|
HBV
|
Hepatitis
B virus
|
|
HES
|
Hypereosinophilic
syndrome
|
|
IBS
|
Irritable
bowel syndrome
|
|
INSTI
|
Integrase
strand transfer inhibitors
|
|
IRA
|
Inflation
Reduction Act
|
|
IV
|
Intravenous
|
|
LAI
|
Long
acting injectables (includes Apretude and
Cabenuva)
|
|
LoE
|
Loss of
exclusivity
|
|
LRTD
|
Lower
respiratory tract disease
|
|
MAPS
|
Multi
antigen presenting system
|
|
MASH
|
Metabolic
dysfunction-associated steatohepatitis
|
|
MMRV
|
Measles,
mumps, rubella and varicella
|
|
Mo-Rez
|
Mocertatug
rezetecan
|
|
mRNA
|
Messenger
ribonucleic acid
|
|
MSI-H
|
Microsatellite
instability high
|
|
NDA
|
New
Drug Application
|
|
OA
|
Older
adults
|
|
Oral
2DR
|
Oral 2
drug regimen (includes Dovato and Juluca)
|
|
PARP
|
Poly
ADP ribose polymerase
|
|
PD-1
|
Programmed
death receptor-1 blocking antibody
|
|
PDUFA
|
Prescription
Drug User Fee Act
|
|
PK
|
Pharmacokinetics
|
|
ppts
|
Percentage
points
|
|
PrEP
|
Pre-exposure
prophylaxis
|
|
PRIME
|
Priority
Medicines
|
|
RCC
|
Refractory
chronic cough
|
|
RI&I
|
Respiratory,
Immunology & Inflammation
|
|
Ris-Rez
|
Risvutatug
rezetecan
|
|
RNS
|
Regulatory
news service
|
|
RSV
|
Respiratory
syncytial virus
|
|
SC
|
Subcutaneous
|
|
SCLC
|
Small
cell lung cancer
|
|
SG&A
|
Selling,
general and administrative expenses, net of other sundry
income
|
|
siRNA
|
Small
interfering RNA
|
|
SITT
|
Single
inhaler triple therapy
|
|
TKI
|
Tyrosine
kinase inhibitor
|
|
TSLP
|
Thymic
stromal lymphopoietin
|
|
ULA
|
Ultra
long acting
|
|
uUTI
|
Uncomplicated
urinary tract infection
|
Product List
|
|
|
|
|
|
Trademark
|
Generic
|
Product Area
|
Indication(s)
|
|
Anoro Ellipta
|
umeclidinium
bromide/vilanterol trifenatate
|
General
medicines
|
COPD
|
|
Apretude
|
cabotegravir
|
Specialty
medicines
|
HIV
prevention
|
|
Arexvy
|
respiratory
syncytial virus vaccine
|
Vaccines
|
Respiratory
syncytial virus vaccination
|
|
Benlysta
(SC and
IV)
|
belimumab
|
Specialty
medicines
|
Systemic
lupus erythematosus, lupus nephritis
|
|
Bexsero
|
meningococcal
group-B vaccine
|
Vaccines
|
Meningitis
group B prophylaxis
|
|
Blenrep
|
belantamab
mafodotin
|
Specialty
medicines
|
Relapsed/refractory
multiple myeloma
|
|
Blujepa
|
gepotidacin
|
General
medicines
|
Uncomplicated
UTI, Uncomplicated Gonorrhoea
|
|
Boostrix
|
diphtheria,
tetanus, acellular pertussis
|
Vaccines
|
Diphtheria,
tetanus, acellular
Pertussis
booster vaccination
|
|
Cabenuva/Vocabria + Rekambys
|
cabotegravir,
rilpivirine
|
Specialty
medicines
|
HIV/AIDS
|
|
Cervarix
|
HPV 16
& 18 virus like particles (VLPs), AS04 adjuvant (MPL +
aluminium hydroxide)
|
Vaccines
|
Human
papilloma virus type 16 and 18
|
|
Dovato
|
dolutegravir/lamivudine
|
Specialty
medicines
|
HIV/AIDS
|
|
Exdensur
|
depemokimab
|
Specialty
medicines
|
Severe
Asthma, CRSwNP
|
|
Flixotide / Flovent
|
fluticasone
propionate
|
General
medicines
|
Asthma
|
|
Fluarix / FluLaval
|
split
inactivated influenza antigens (2 virus subtypes A and 2 subtype
B)
|
Vaccines
|
Seasonal
influenza prophylaxis
|
|
Hibsago
|
bepirovirsen
|
Specialty
medicines
|
chronic
hepatitis B (CHB)
|
|
Infanrix/Pediarix
|
diphtheria,
tetanus, pertussis, polio, hepatitis B, haemophilus influenzae type
B (EU)
|
Vaccines
|
Prophylaxis
against diphtheria, tetanus,
pertussis,
polio, hepatitis B, Haemophilus influenzae type B (EU)
|
|
Jemperli
|
dostarlimab
|
Specialty
medicines
|
dMMR/MSI-H
recurrent/ advanced endometrial cancer, dMMR solid
tumours
|
|
Jideytro
|
zidesamtinib
|
Specialty
medicines
|
ROS1-positive
non-small cell lung cancer (NSCLC),
|
|
Juluca
|
dolutegravir/rilpivirine
|
Specialty
medicines
|
HIV/AIDS
|
|
Menveo
|
meningococcal
group A, C, W-135 and Y conjugate vaccine
|
Vaccines
|
Meningitis
group A, C, W-135 and Y prophylaxis
|
|
Nucala
|
mepolizumab
|
Specialty
medicines
|
Asthma,
COPD, CRSwNP, EGPA, HES
|
|
Ojjaara/Omjjara
|
momelotinib
|
Specialty
medicines
|
Myelofibrosis
in patients with anaemia
|
|
Penmenvy
|
meningococcal
groups A, B, C, W, and Y vaccine
|
Vaccines
|
Meningitis
group A, B, C, W-135 and Y prophylaxis
|
|
Priorix, Priorix Tetra, Varilrix
|
live
attenuated MMR, varicella and MMRV vaccines
|
Vaccines
|
Measles,
mumps, rubella and chickenpox prophylaxis
|
|
Relvar/Breo Ellipta
|
fluticasone
furoate/vilanterol trifenatate
|
General
medicines
|
Asthma,
COPD
|
|
Rotarix
|
human
rotavirus RIX4414 strain
|
Vaccines
|
Rotavirus
prophylaxis
|
|
Rukobia
|
fostemsavir
|
Specialty
medicines
|
HIV/AIDS
|
|
Seretide / Advair
|
salmeterol
xinafoate, fluticasone propionate
|
General
medicines
|
Asthma,
COPD
|
|
Shingrix
|
zoster
vaccine recombinant, adjuvanted
|
Vaccines
|
Herpes
zoster (shingles)
|
|
Synflorix
|
conjugated
pneumococcal polysaccharide
|
Vaccines
|
Prophylaxis
against invasive disease, pneumonia, acute otitis
media
|
|
Tivicay
|
dolutegravir
|
Specialty
medicines
|
HIV/AIDS
|
|
Trelegy Ellipta
|
fluticasone
furoate/vilanterol trifenatate/umeclidinium bromide
|
General
medicines
|
COPD,
asthma
|
|
Triumeq
|
dolutegravir,
lamivudine and abacavir
|
Specialty
medicines
|
HIV/AIDS
|
|
Ventolin
|
salbutamol
sulphate
|
General
medicines
|
Asthma,
COPD
|
|
Zejula
|
niraparib
|
Specialty
medicines
|
Ovarian
cancer
|
Brand names appearing in italics throughout this document are
trademarks of GSK or associated companies or used under licence by
the Group.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
28, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|